



**Capacity for the management of kidney failure in the ISN
Western Europe region: Report from the 2023 ISN Global
Kidney Health Atlas (ISN-GKHA)**

Journal:	<i>Kidney International Supplements</i>
Manuscript ID	Draft
Article Type:	ISN 2024 Global Kidney Health Atlas
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Pippias, Maria; University of Bristol Faculty of Medicine and Dentistry, Population Health Sciences; Southmead Hospital, Renal Unit Alfano, Gaetano; Azienda Ospedaliero-Universitaria di Modena, Struttura Complessa di Nefrologia e Dialisi; University of Modena and Reggio Emilia, Surgical, Medical and Dental department of Morphological Sciences Kelly, Dearbhla; Mater Misericordiae University Hospital, Department of Intensive Care Medicine Soler Romeo, Maria José; Vall d'Hebron Hospital, De Chiara, Letizia; University of Florence, Clinical and Experimental Biomedical Sciences; U Olanrewaju, Timothy; University of Ilorin, Department of Medicine; Utrecht University, University of Ilorin Arruebo, Silvia; International Society of Nephrology Bello, Aminu; University of Alberta, Caskey, Fergus; University of Bristol, Population Health Sciences; North Bristol NHS Trust, Damster, Sandrine; International Society of Nephrology Donner, Jo-Ann; The International Society of Nephrology, Jha, Vivekanand; Postgraduate Medical Institute, Nephrology Johnson, David; Princess Alexandra Hospital, Department of Nephrology; Translational Research Institute, ; Metro South and Ipswich Nephrology and Transplant Services (MINTS), Princess Alexandra Hospital Levin, Adeera; University of British Columbia, Medicine; Malik, Charu; International Society of Nephrology Nangaku, Masaomi; University of Tokyo Okpechi, Ikechi G.; University of Alberta, Department of Medicine Tonelli, Marcello; University of Calgary, Medicine (Nephrology) Ye, Feng; University of Alberta Faculty of Medicine and Dentistry Coppo, Rosanna; Fondazione Ricerca Molinette, Nephrology, Dialysis, Transplant; Città della Salute e della Scienza di Torino, Regina Margherita Hospital, Nephrology, Dialysis and Transplantation Lightstone, Liz; Imperial College School of Medicine, Renal Section, Division of Medicine, Faculty of Medicine Amouzegar, Atefeh; Iran University of Medical Sciences Faculty of Medicine Anders, Hans-Joachim; Klinikum Univ Munchen, Baharani, Jyoti; University Hospitals Birmingham NHS Foundation Trust</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	<p>Banerjee, Debasish; St George's University Hospitals NHS Foundation Trust, Renal and Transplantation Unit; University of London St George's Molecular and Clinical Sciences Research Institute, Cardiology Clinical Academic Group</p> <p>Bikbov, Boris; A.I.Evdokimov Moscow State University of Medicine and Dentistry, Chair of Nephrology; Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, 2. Department of Nephrology Issues of Transplanted Kidney</p> <p>Brown, Edwina; Hammersmith Hospital, Imperial College Kidney and Transplant Institute</p> <p>Cho, Yeoungjee; Princess Alexandra Hospital, Department of Nephrology</p> <p>Claes, Kathleen; KU Leuven University Hospitals Leuven, Nephrology</p> <p>Clyne, Naomi; Skåne University Hospital Lund</p> <p>Dauids, Mogamat; Stellenbosch University, Division of Nephrology; Stellenbosch University</p> <p>Davison, Sara; University of Alberta, Medicine/Nephrology</p> <p>Diongole, Hassane M.; National Hospital Zinder, Department of Medicine; Faculty of Health Sciences, Department of Medicine</p> <p>DIVYAVEER, SMITA; Post Graduate Institute of Medical Education and Research, NEPHROLOGY</p> <p>Dreyer, Gavin; Barts Health NHS Trust,</p> <p>Dudley, Jan; Bristol Royal Hospital for Children</p> <p>Ekrikpo, Udeme; University of Uyo, Department of Medicine;</p> <p>Ethier, Isabelle; Centre Hospitalier de l'Université de Montréal, Department of Medicine; Centre de Recherche du Centre Hospitalier de l'Université de Montreal,</p> <p>Evans, Rhys; Barts Health NHS Trust, Renal Medicine and Transplantation</p> <p>Fan, Stanley; Barts Health NHS Trust, Renal Unit</p> <p>Fung, Winston Wing Shing; The Chinese University of Hong Kong, Medicine & Therapeutics</p> <p>Gallieni, Maurizio; Università degli Studi di Milano, DIBIC "L. Sacco"; ASST Fatebenefratelli Sacco, Nephrology and Dialysis Unit</p> <p>Ghimire, Anukul; University of Alberta,</p> <p>Houston, Ghenette; University of Alberta Faculty of Medicine & Dentistry</p> <p>HTAY, HTAY; Singhealth, Renal Medicine; Princess Alexandra Hospital,</p> <p>Ibrahim, Kwaifa Salihu ; Wuse District Hospital, Medicine; Nile University of Nigeria, Internal Medicine</p> <p>Irish, Georgina; The University of Adelaide Faculty of Health and Medical Sciences</p> <p>Jindal, Kailash; University of Alberta, Nephrology</p> <p>Khwaja, Arif; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Kidney Institute;</p> <p>Lalji, Rowena; Queensland Children's Hospital</p> <p>Liakopoulos, Vassilios; Aristotle University of Thessaloniki School of Medicine, Division of Nephrology and Hypertension, 1st Department of Internal Medicine; Otto-von-Guericke-University Magdeburg, , Clinic of Nephrology and Hypertension, Diabetes and Endocrinology</p> <p>Luyckx, Valerie; Chris Hani Baragwanath Hospital, University of the Witwatersrand</p> <p>Macia, Manuel; Hospital Nuestra Señora de la Candelaria, Nephrology</p> <p>Marti, Hans-Peter; University of Bergen, Department of Clinical Medicine; Haukeland University Hospital, Department of Medicine</p> <p>Messa, Piergiorgio</p> <p>Mueller, Thomas; University Hospital Zurich, Nephrology</p> <p>NALADO, AISHATU; Aminu Kano Teaching Hospital, MEDICINE; University of the Witwatersrand, Medicine</p> <p>Neuen, Brendon; George Institute for Global Health,</p> <p>Nitsch, Dorothea; London School of Hygiene & Tropical Medicine, Department of Epidemiology and Population Health</p> <p>Nolasco, Fernando; Nova University of Lisbon, Faculty of Medical</p>
--	--

	<p>Sciences Oberbauer, Rainer; Medical University Vienna, Internal Medicine III (Nephrology) Osman, Mohamed; University of Alberta Faculty of Medicine and Dentistry, Division of Nephrology Papagianni, Aikaterini; Aristotle University, Department of Nephrology Petrova, Anna; Bogomolets National Medical University Piccoli, Giordina; Nephrology Unit, Clinical and Biological Sciences; Plant, William; Cork University Hospital, Renal Medicine Remuzzi, Giuseppe; Azienda Ospedaliera Papa Giovanni XXIII, Unit of Nephrology and Dialysis; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Riaz, Parnian; McMaster University Faculty of Health Sciences Roelofs, Joris; Academic Medical Centre, Pathology Rudnicki, Michael; Medical University Innsbruck, Nephrology Saad, Syed; University of Alberta Sakajiki, Aminu; Usmanu Danfodiyo University Teaching Hospital, Department of Medicine Scheppach, Johannes; Charité Universitätsmedizin Berlin, ; Johns Hopkins University, See, Emily; Princess Alexandra Hospital, Nephrology Shroff, Rukshana; Great Ormond Street Hospital, Solbu, Marit; UiT The Arctic University of Norway Sozio, Stephen; Johns Hopkins University School of Medicine, Division of Nephrology Strippoli, Giovanni; University of Sydney School of Public Health, ; University of Bari, Medical Scientific Office Taal, Maarten; University of Nottingham Tataw Ashu, James; Geneva University Hospitals Tiv, Sophanny; University of Alberta Faculty of Medicine & Dentistry Tungsanga, Somkanya; University of Alberta, Medicine; Chulalongkorn University Faculty of Medicine, van der Net, Jeroen; Albert Schweitzer Ziekenhuis Vanholder, Raymond; University Hospital Gent, Department of Nephrology, Pneumology and Intensive Care Medicine Viecelli, Andrea; Princess Alexandra Hospital, Nephrology Vinen, Katie; King's College Hospital Charity Vogt, Bruno; University Hospital Inselspital, Dept of Nephrology, Hypertension and Clinical Pharmacology Wainstein, Marina; University of Queensland Weinstein, Talia; Tel Aviv University Wheeler, David; University College London, Centre for Nephrology Yeung, Emily; Monash Health Zaidi, Deenaz; University of Alberta, Department of Medicine</p>
Subject Area:	Chronic Kidney Injury
Twitter Handle:	
Keywords:	chronic kidney disease, chronic kidney failure

SCHOLARONE™
Manuscripts

1
2
3 **Capacity for the management of kidney failure in the International Society of**
4 **Nephrology Western Europe region: Report from the 2023 ISN Global Kidney**
5 **Health Atlas (ISN-GKHA)**
6
7
8
9

10
11
12 Maria Pippias PhD, Bristol Medical School: Population Health Sciences, University of
13
14 Bristol, Bristol, UK; Renal Unit, North Bristol NHS Trust, Bristol, UK

15
16
17 Gaetano Alfano MD, Nephrology Dialysis and Transplant Unit, Azienda Ospedaliero
18
19 - Universitaria di Modena, Modena, Italy

20
21 Dearbhla M. Kelly DPhil, Wolfson Centre for the Prevention of Stroke and Dementia,
22
23 University of Oxford, John Radcliffe Hospital, Oxford, UK; Department of
24
25 Intensive Care Medicine, John Radcliffe Hospital, Oxford, UK

26
27
28 Maria Jose Soler MD, Vall d'Hebron University Hospital, Vall d'Hebron Institute of
29
30 Research, CSUR National Unit of Expertise for Complex Glomerular Diseases
31
32 of Spain, Barcelona, Spain

33
34
35 Letizia De Chiara PhD, Department of Experimental and Clinical Biomedical
36
37 Sciences "Mario Serio", University of Florence, Florence, Italy

38
39
40 Timothy O Olanrewaju MD, Division of Nephrology, Department of Medicine, College
41
42 of Health Sciences, University of Ilorin, Ilorin, Nigeria; Julius Global Health,
43
44 Julius Center for Health Sciences and Primary Care, University Medical Center
45
46 Utrecht, Utrecht University, Utrecht, The Netherlands

47
48
49 Silvia Arruebo, The International Society of Nephrology, Brussels, Belgium

50
51 Aminu K. Bello PhD,* Division of Nephrology and Immunology, Faculty of Medicine
52
53 and Dentistry, University of Alberta, Edmonton, Alberta, Canada

54
55
56 Fergus J. Caskey MD, Population Health Sciences, Bristol Medical School,
57
58 University of Bristol, Bristol, UK
59
60

1
2
3 Sandrine Damster, The International Society of Nephrology, Brussels, Belgium

4
5 Jo-Ann Donner, The International Society of Nephrology, Brussels, Belgium

6
7 Vivekanand Jha MD, George Institute for Global Health, University of New South

8
9
10 Wales (UNSW), New Delhi, India; School of Public Health, Imperial College,

11
12 London, UK; Manipal Academy of Higher Education, Manipal, India

13
14 David W. Johnson PhD,* Department of Kidney and Transplant Services, Princess

15
16 Alexandra Hospital, Brisbane, Queensland, Australia; Centre for Kidney

17
18 Disease Research, University of Queensland at Princess Alexandra Hospital,

19
20 Brisbane, Queensland, Australia; Translational Research Institute, Brisbane,

21
22 Queensland, Australia; Australasian Kidney Trials Network at the University of

23
24 Queensland, Australia

25
26 Adeera Levin MD, Division of Nephrology, Department of Medicine, University of

27
28 British Columbia, Vancouver, British Columbia, Canada

29
30 Charu Malik PhD, The International Society of Nephrology, Brussels, Belgium

31
32 Masaomi Nangaku MD, Division of Nephrology and Endocrinology, The University of

33
34 Tokyo Graduate School of Medicine, Tokyo, Japan

35
36 Ikechi G. Okpechi PhD, Division of Nephrology and Immunology, Faculty of Medicine

37
38 and Dentistry, University of Alberta, Edmonton, Alberta, Canada; and Division

39
40 of Nephrology and Hypertension, University of Cape Town, Cape Town, South

41
42 Africa; Kidney and Hypertension Research Unit, University of Cape Town,

43
44 Cape Town, South Africa

45
46 Marcello Tonelli MD, Department of Medicine, University of Calgary, Calgary,

47
48 Alberta; Canada and Pan-American Health Organization/World Health

49
50 Organization's Collaborating Centre in Prevention and Control of Chronic

51
52 Kidney Disease, University of Calgary, Calgary, Alberta, Canada

1
2
3 Feng Ye MSc, Division of Nephrology and Immunology, Faculty of Medicine and
4
5 Dentistry, University of Alberta, Edmonton, Alberta, Canada

6
7
8 Rosanna Coppo MD,+ Fondazione Ricerca Molinette, Regina Margherita Hospital,
9
10 Turin, Italy

11
12 Liz Lightstone PhD,+ Centre for Inflammatory Disease, Department of Immunology
13
14 and Inflammation, Imperial College London, London, UK

15
16 and the Regional Board and ISN-GKHA Team Authors (Appendix 1)

17
18
19
20
21 * Co-chairs for International Society of Nephrology Global Kidney Health Atlas (ISN-
22
23 GKHA)

24
25
26 + Co-senior authors

27
28
29
30
31 **Corresponding author:**

32
33 Maria Pippias: Renal Unit, Southmead Hospital, Southmead Road, Bristol BS10
34
35 5NB, UK. Tel: 01174147696, maria.pippias@bristol.ac.uk ORCID: 0000-0001-7469-
36
37 4955

38
39
40
41
42 **Word count without abstract, references, tables, and figures: 4100**

43
44 **Running title:** ISN-GKHA – Western Europe

45
46
47 **Keywords (3-6):** chronic kidney disease, end-stage kidney disease, dialysis, kidney
48
49 transplantation, kidney registries, Europe.

50
51
52
53
54 **Funding Source:** This work was supported by the International Society of
55
56 Nephrology (Grant RES0033080 to the University of Alberta).

Abstract (248 words)

Western Europe boasts advanced healthcare systems, robust kidney care guidelines, and a well-established healthcare workforce. Despite this, significant disparities in kidney replacement therapy incidence, prevalence, and transplant access exist. This paper presents the third International Society of Nephrology Global Kidney Health Atlas's findings on kidney care availability, accessibility, affordability, and quality in 22 Western European countries, representing 99% of the region's population. The known chronic kidney disease (CKD) prevalence across Western Europe averages 10.6%, slightly above the global median. Cardiovascular diseases account for a substantial portion of CKD-related deaths. Kidney failure incidence varies. Government health expenditure differs, however, most countries offer government-funded acute kidney injury, dialysis, and kidney transplantation care. Hemodialysis and peritoneal dialysis are universally available, with variations in the number of dialysis centers. Kidney transplantation is available in all countries (except for three microstates), with variable transplant center prevalence. Conservative kidney management is increasingly accessible. The region's kidney care workforce is substantial, exceeding global averages, however, workforce shortages are reported. Barriers to optimal kidney care include limited workforce capacity, lack of surveillance mechanisms, and suboptimal integration into national non-communicable disease strategies. Policy recognition of CKD as a health priority varies across countries. While Western Europe exhibits strong kidney care infrastructure, opportunities for improvement exist, particularly in CKD prevention, surveillance, awareness, and policy implementation. Efforts to improve CKD care should include automated detection, educational support, and enhanced workflows.

1
2
3 Based on these findings, healthcare professionals, stakeholders, and policymakers
4
5 are called to act to enhance kidney care across the region.
6
7
8
9

10 **Introduction**

11
12 Western Europe has established functional healthcare systems, produced
13 numerous kidney guidelines, and achieved a higher prevalence of healthcare
14 professionals, greater availability of medicines, and more widespread universal
15 healthcare coverage compared to other world regions.¹ For almost 60 years, the
16 European Renal Association (ERA) Registry has been collecting data on kidney
17 replacement therapy (KRT) modalities [i.e., hemodialysis (HD), peritoneal dialysis
18 (PD), and transplantation] via national and regional kidney registries from 36
19 countries in Europe.² Despite this high level of kidney care and KRT surveillance
20 systems, the ERA Registry and the International Society of Nephrology Global
21 Kidney Health Atlas (ISN-GKHA) have highlighted significant disparities in kidney
22 care across Western European countries.^{1,3-7} The incidence and prevalence of
23 treated kidney failure, and access to kidney transplantation vary considerably across
24 the region without clear explanation.^{4,7} For people living with kidney failure in
25 Western Europe, HD remains the dominant dialysis modality, with significant
26 variations across countries.^{8,9} Home-therapies, such as home HD and PD, are
27 underutilized with significant prevalence variations across countries,⁸ and access to
28 kidney transplantation is not equitable across Western Europe.³
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Since the 2019 ISN-GKHA, kidney medicine across Europe has faced new
55 challenges, including recovery from the COVID-19 pandemic, the war in Ukraine,^{10,11}
56 the Turkey–Syria earthquake and rising global temperatures,¹² with heatwaves seen
57
58
59
60

1
2
3 across Europe. These challenges have had direct effects on the care of people with
4 kidney disease, though the degree to which they have affected kidney care needs
5 further clarification.
6
7
8
9

10
11
12 The ISN-GKHA is in its third global iteration. The aim of ISN-GKHA is to
13 understand, compare and monitor how different countries around the world detect,
14 treat, monitor, and advocate for people with kidney disease.¹³ In this second Western
15 Europe-specific report, data from the 2023 ISN-GKHA is presented on the
16 availability, accessibility, affordability, and quality of kidney failure care across the
17 ISN Western Europe region. The methodology for this report is described in detail
18 elsewhere.¹⁴
19
20
21
22
23
24
25
26
27
28
29

30 31 **Results**

32
33 Results of this study are presented in tables and figures and broadly
34 summarized into two categories: desk research (Table 1,^{15,16} Table 2,^{17,18} Table 3,¹⁹⁻
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26 Table 4,²⁷⁻⁴⁵ and Supplementary Table S1,⁴⁶) and survey administration (Tables 5-
7, Figures 1-4, and Supplementary Tables S2-10).

42 **Study setting**

43
44 For this report, the ISN's regional classification of countries in Western
45 Europe was utilized, which includes countries bordering the Mediterranean Sea.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Western Europe is one of the richest regions in the world, although variability among
countries is observed. Luxembourg, Ireland, Liechtenstein, Switzerland, Norway, and
Denmark all appear in the top ten countries by gross domestic product (GDP) per
capita (Table 1).¹⁵ Greenland and Faroe Islands are considered as their own
countries by the World Bank and the data analysis was done on this basis, however

1
2
3 they are currently part of the Kingdom of Denmark. The Social Progress Index (SPI)
4
5 measures the extent to which countries provide for the social and environmental
6
7 needs of their citizens. Fifteen of the top twenty countries in the SPI list are in
8
9 Western Europe,⁴⁷ whilst 14 of the top 20 world happiness report 2023 are Western
10
11 European countries.⁴⁸
12
13
14
15
16

17 **The current status of kidney care in the ISN Western Europe**

18
19 Western Europe is the world region with the highest prevalence of medical
20
21 doctors [42.3 [(interquartile range, IQR: 34.9-50.5)] per million population (pmp) and
22
23 nurses [117.8 pmp (IQR: 88.5-167.8)], compared to the median reported worldwide
24
25 workforce [doctors, 17.7 pmp (IQR: 3.8-32.87), nurses 36.2 pmp (IQR: 14.4-66.6)]
26
27 (Supplementary Table S1).⁴⁶ According to the ERA 2020 annual report the incidence
28
29 of KRT for the treatment of kidney failure is falling in some Western European
30
31 countries, whilst the prevalence continues to grow, currently standing at 1,173 pmp.⁸
32
33 Individuals aged over 65 years make up almost half (45%) of the prevalent KRT
34
35 population.⁸ Diabetes, hypertension, and renovascular disease account for 26% of
36
37 the causes of kidney failure in the prevalent population with
38
39 glomerulonephritis/sclerosis accounting for 18%.⁸ Almost half of the Western
40
41 European 2020 prevalent KRT population (47%) were living with a kidney
42
43 transplant.⁸ Five-year adjusted patient survival is 46.8% [95% confidence interval,
44
45 (95%CI): 46.5-47.1] on dialysis, 92.1% (95%CI: 91.9-92.4) after a first deceased
46
47 donor transplant and 95.0% (95%CI: 94.6-95.4) after a first living donor transplant.⁸
48
49
50
51
52
53
54
55

56 **Literature review data for countries in the ISN Western Europe region**

57 **The burden of chronic kidney disease (CKD) and kidney failure**

58
59
60

1
2
3 The prevalence of CKD, defined as stages G1-5/A1-3, ranged from 7.9% (95%CI:
4 7.4-8.6) in Iceland to 14.7% (95%CI: 12.7-16.9) in Greece with a median of 10.6%
5 (IQR: 9.6-11.6) (Table 2).¹⁷ This was slightly higher than the median for all regions at
6 9.5% (IQR: 5.9-11.7) (Table 2).¹⁷ The proportion of deaths attributed to CKD was
7 less than 2% in the UK (1.3% [95%CI: 1.1-1.3]), Finland (1.3% [95%CI: 1.1-1.4]),
8 Iceland (1.6% [95%CI: 1.3-1.8]) and Norway (1.9% [95%CI: 1.6-2.0]), whereas it was
9 over 4% in Austria (4.1% [95%CI: 3.5-4.5]) and Israel 5.8% [(95%CI: 5.0-6.4)],
10 (Table 2).¹⁷ The median percentage of deaths worldwide attributed to CKD was 2.4%
11 (IQR: 1.6-3.9) (Table 2).¹⁷

12 Risk factors associated with CKD also varied substantially across Europe with
13 the proportion of obesity ranging from a fifth of the adult population in Switzerland
14 (21.2% [95%CI: 17.3-25.3]) to almost a third in Malta (31.0% [95%CI: 25.1-37.0]).
15 Hypertension ranged from a sixth of the United Kingdom's (UK's) adult population
16 (15.2% [95%CI: 12.2-18.3]) to a quarter of Portugal's adult population (24.4%
17 [95%CI: 18.2-31.2]). One in ten adults were reported to smoke in Sweden (11.4%
18 [95%CI: 10.7-12.2]) whereas this was almost one in three adults in Greece (31.2%
19 [95%CI: 28.9-33.5]) (Table 2).¹⁸

20 The incidence of the population on KRT failure (dialysis and kidney transplantation)
21 ranged from less than 100 pmp in Ireland, Finland, and Switzerland (88 pmp, 94 pmp
22 and 99 pmp, respectively) to over 250 pmp in Portugal and Greece (260 pmp and
23 269 pmp, respectively). Similarly, the prevalence of treated kidney failure ranged
24 from less than 900 pmp in Luxembourg, Israel, and Iceland (522 pmp, 755 pmp, and
25 810 pmp, respectively) to over 1,400 pmp in Greece and Portugal (1,413 pmp and
26 2,008 pmp, respectively) (Table 3).¹⁹⁻²⁶ Whilst the median incidence of the population

1
2
3 on KRT in the ISN Western Europe region (135.0 pmp [IQR: 106-170]) was lower
4 than the overall global median (145.5 pmp [IQR:107.0-212.5]), the median
5 prevalence of kidney failure was higher (1,034.0 pmp [IQR: 957-1,337] for Western
6 Europe and 822.8 pmp [IQR: 556.0-1114.0] worldwide).¹⁹⁻²⁶
7
8
9
10
11
12
13
14

15 Most individuals commenced KRT on chronic HD, however the incidence
16 differed considerably from less than 70 pmp in Denmark, Sweden, Finland, and
17 Iceland (61.8 pmp, 68.4 pmp, 69.2 pmp, and 69.3 pmp, respectively) to over 140
18 pmp in France, Belgium, and Greece (146.1 pmp, 175.8 pmp and 255.1 pmp,
19 respectively). Much smaller proportions commenced KRT on PD, with an incidence
20 of less than 15 pmp in Austria, Greece, and Switzerland (10.6 pmp, 12.7 pmp, and
21 12.9 pmp). Only Sweden and Denmark had an incidence of greater than 35 pmp
22 (35.1 pmp and 36.1 pmp respectively). Very few individuals received pre-emptive
23 kidney transplants, which were less than 5 pmp in Greece, Belgium, and Finland (1.1
24 pmp, 2.9 pmp and 4.3 pmp, respectively). Pre-emptive kidney transplantation was
25 highest in the UK, Iceland, and the Netherlands (12.8 pmp, 13.9 pmp and 16.8 pmp,
26 respectively) (Table 3).¹⁹⁻²⁶
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 The prevalence of chronic HD was lowest in the Nordic countries (Iceland,
46 Norway, Finland, Sweden) and the Netherlands (196.9 pmp, 252.2 pmp, 306.8 pmp,
47 316.1 pmp, 322.7 pmp, respectively) and highest in Belgium, Germany, Portugal,
48 and Greece (708.7 pmp, 768.1 pmp, 871.3 pmp, 1,100.5 pmp, respectively). The
49 prevalence of chronic PD was only 4.7 pmp in Luxembourg, and less than 40 pmp in
50 Germany, Ireland, and Switzerland (38.8 pmp, 39.2 pmp, and 39.3 pmp,
51 respectively), whereas it was over 80 pmp in Sweden, Denmark, and Italy (85.1 pmp,
52
53
54
55
56
57
58
59
60

1
2
3 87.2 pmp, 89.3 pmp, respectively). Three countries had prevalences of individuals
4 living with a kidney transplant of less than 500 pmp, Greece, Italy, and Israel (248.9
5 pmp, 476.0 pmp, 492.0 pmp, respectively), and three countries had prevalences of
6 over 700 pmp Portugal, UK, and Spain (707.0 pmp, 735.0 pmp, and 751.2 pmp,
7 respectively). Whilst the incidence of living donor kidney transplantation was less
8 than 15 pmp for most countries, it was 26.3 pmp in the Netherlands and 37.2 pmp in
9 Israel (Table 3).¹⁹⁻²⁶

21 **Overview of GDP and government health expenditure**

22
23
24 The total health expenditure as a percentage of GDP ranged from 5.4%, 6.7%
25 and 6.7% in Luxembourg, Andorra, and Ireland, respectively, to 11.1%, 11.3% and
26 11.7% in France, Switzerland, and Germany, respectively, with an average of 9.3%.
27
28 Total health spending per person ranged six-fold from US\$1,599 in Greece to
29 US\$9,801 in Switzerland, with a median of US\$5,088 (IQR:3,259-5,851) (Table 1).¹⁵
30
31 This was considerably higher than the overall health spending of all regions of
32 US\$353 (IQR:76-1,270) (Table 1).¹⁵ Government health spending per person ranged
33 seven-fold from US\$909 in Greece to US\$6,300 in Norway, with a median of
34 US\$3,798 (IQR: 2,470 – 4,701) (Table 1).¹⁶ This resulted in an out-of-pocket health
35 spending per person ranging from US\$358 in Andorra to US\$2,532 in Switzerland
36 with a median spend of US\$637 (IQR: 589-800) per person (Table 1).¹⁶ The
37 demographics of the countries in the ISN Western Europe region can be found in
38 Tables 1-3.¹⁵⁻²⁶

56 **Cost of KRT**

1
2
3 The annual cost of HD varied considerably across the region from US\$24,419
4 in Iceland to US\$94,085 in the UK. Likewise, the annual cost of PD ranged from
5 US\$18,959 in Ireland to US\$83,070 in the UK. The first year after kidney
6 transplantation was cheapest in the UK (US\$19,255) and most expensive in
7 Germany (US\$126,993). Beyond the first year, the differences in the costs of kidney
8 transplantation were striking, ranging from US\$578 in Finland to US\$41,254 in
9 Norway (Table 4).²⁷⁻⁴⁵

21 **Survey response data for the ISN Western Europe region**

23 **Characteristics of participating countries**

24 Responses to the survey were received from 22 of 29 countries (75.9%) in the
25 ISN Western Europe region: Andorra, Austria, Belgium, Denmark, Finland, France,
26 Germany, Greece, Iceland, Ireland, Israel, Italy, Liechtenstein, Luxembourg, Malta,
27 the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, and the UK (Figure
28 1). These 22 countries had a combined population of 439.5 million people which
29 represented 99% of the region's population and covered 3.8 million square
30 kilometers. All countries were classified as high income by the World Bank, with a
31 GDP based on purchasing power parity ranging from US\$3.3 billion (2021 United
32 States dollars), US\$5 billion, and US\$21.5 billion, in Andorra, Liechtenstein and
33 Iceland, respectively, to US\$3.34 trillion, US\$3.42 trillion, and US\$4.82 trillion in the
34 UK, France, and Germany, respectively (Table 1).^{15,49}

53 **Health financing for kidney care**

54 In eighteen countries (82%), acute kidney injury (AKI), dialysis, and kidney
55 transplantation were publicly funded by the government and free at the point of
56
57
58
59
60

1
2
3 delivery (Table 5). Liechtenstein relied solely on a private (health insurance) scheme,
4
5
6 whereas transplantation in Ireland was publicly funded by the government but
7
8 included some fees. Sixteen countries (73%) had healthcare systems that were
9
10 publicly funded by the government and free at the point of delivery for individuals
11
12 with non-KRT CKD. Two countries (9%) were publicly funded by the government but
13
14 included some fees. Two countries (9%) had a mixture of public and private funding
15
16 systems and only one country (Liechtenstein) had a solely private and out-of-pocket
17
18 funding system for non-KRT CKD. This was considerably different from the rest of
19
20 the world where only 27% of non-KRT CKD was publicly funded from the
21
22 government and 37% was a mixture of public and private financing. Within the ISN
23
24 Western Europe region, 19 (86%) countries had government publicly funded and
25
26 free at the point of delivery chronic HD, whereas this was only 45% of countries
27
28 worldwide (Supplementary Table S2).
29
30
31
32
33
34

35
36 In the 2023 ISN-GKHA, funding of medications for CKD were free at the point
37
38 of delivery in Austria, Denmark, Italy, and Malta (18%), whereas funding for
39
40 medications for dialysis were free at the point of delivery in Austria, Denmark,
41
42 Greece, Italy, Israel, Malta, and Switzerland (32%) (Table 5). Medications for people
43
44 with CKD and for people receiving dialysis were publicly funded by the government
45
46 but with some fees in 55% and 45% of countries, respectively. These were much
47
48 higher rates of government funding of medications than the worldwide median (33%
49
50 and 28%, respectively). Likewise, 72% of medications for kidney transplant
51
52 recipients were either publicly funded and free at the point of delivery or with some
53
54 fees (Table 5), which was higher than the worldwide median of 52%.
55
56
57
58
59
60

Availability of services for the delivery of kidney care

HD and PD were available in all countries of the ISN Western Europe region. The median number of chronic HD centers was 7.7 pmp though this ranged from 1.0 pmp in the UK to 19.0 pmp in Greece (and 25.2 pmp in the microstate of Liechtenstein), (Table 6, Figure 2). Home HD for adults and pediatrics was available in 77% of countries (generally not available in Iceland and Israel and not available in Greece, Luxembourg, or Malta). This was higher than the worldwide average of 19%. Chronic PD was available in all countries (2.7 pmp), however acute PD was only available in 15 countries (68%) (Supplementary Table S3).

Kidney transplantation, both from living and deceased donors, was available in 18 countries (but not in the microstates and small countries of Andorra, Liechtenstein, or Luxembourg) (Table 6, Figure 2). These 18 countries all had national waiting lists except Spain which only had regional waiting lists. The availability of kidney transplantation centers for the region's countries was 0.69 pmp, ranging from 0.12 pmp in Switzerland to 0.85 pmp in Spain. Kidney transplantation centers were more common in Malta (2.2 pmp) and Iceland (2.8 pmp), however both countries had populations of fewer than 500,000. Pediatric transplantation was available in 17 countries (77%).

Conservative kidney management (CKM), defined as a planned, holistic, patient-centered care for people living with CKD stage 5 which was a shared decision between the healthcare worker and the patient, was generally available in 21 (95%) countries This is higher than the worldwide median of 45% (Supplementary Table S4).

Health workforce for the delivery of kidney care

In all countries bar two microstates (91%), nephrologists were primarily responsible for the medical care of individuals with kidney failure. This was slightly higher than the overall global average of 87%. The median number of nephrologists in the ISN Western Europe region was 25.0 (IQR: 16.4-33.9) pmp, which was over double the median number worldwide (11.8 pmp [IQR: 1.8-24.8]). Within the region, the median prevalence of nephrologists ranged from 11.8 pmp in Ireland to 53.0 pmp in Spain (excluding the microstates). Likewise, the median prevalence of nephrology trainees ranged from 0.59 pmp in Germany to 49.1 pmp in Italy (Table 6). The median prevalence of pediatric nephrologists was 1.6 pmp (IQR: 0.96-2.2), which was over double the global median prevalence of pediatric nephrologists (0.69 pmp [IQR:0.03-1.8]).

There were widespread shortages of healthcare providers for kidney failure across the region (Figure 3). Only 10 countries (45%) reported sufficient nephrologists, and only 5 countries (23%) reported sufficient pediatric nephrologists. Sixteen countries (73%) reported a shortage of transplant surgeons and hemodialysis access surgeons, and 17 countries (77%) reported a shortage of surgeons for PD access. Thirteen countries (59%) required additional counsellors or psychologists and 13 countries (59%) required additional dialysis nurses.

Health information systems, early identification mechanisms for kidney disease, advocacy, and policy for kidney disease

1
2
3 Availability of nephrologists (59%), patient knowledge and attitude (55%),
4 physician availability, access, knowledge, and attitude (50%), and a lack of political
5 will and enabling policies (45%) were the top four cited barriers to optimal kidney
6 care in the ISN Western Europe region (Supplementary Table S5).
7
8
9
10
11
12
13

14 Country level national health policies for kidney care were variable in the
15 region with fourteen countries (64%) stating that their country had a national strategy
16 for non-communicable diseases (NCD) (Supplementary Table S6). Only ten
17 countries (45%) stated that their country had a national strategy for improving the
18 care of people with CKD with half saying that this strategy was incorporated into a
19 NCD strategy (Supplementary Table S6). Only five countries (23%) felt that CKD
20 was a recognized health priority by their country's government which was almost half
21 that of the worldwide opinion (48%). This was the same for AKI (23%) though the
22 worldwide opinion was also lower at 19%. The number of countries that felt their
23 governments recognized kidney failure and/or KRT as a health priority was higher at
24 64% but this still left eight countries (36%) believing it was not recognized as a
25 health priority.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Dialysis and transplant registries were available in all countries except for the
45 microstates of Andorra and Liechtenstein. CKD registries were less prevalent, only
46 being available in six countries (27%), whereas AKI and CKM registries were only
47 available in two countries (9%) (Table 7).
48
49
50
51
52
53
54
55

56 **Causes of hospitalization and death among people living with kidney failure on** 57 **dialysis** 58 59 60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Seventy-three percent of countries reported a mortality of less than 10% in the first year of HD and PD. The commonest cause of death was cardiovascular disease (Supplementary Tables S7-S8). Approximately half of the countries reported less than 30% of people receiving HD or PD had at least one hospitalization event in the first year of dialysis. The commonest causes of hospitalization amongst people receiving HD were cardiovascular disease (59% of countries), and access malfunction (14% of countries) (Supplementary Table S9). The commonest cases of hospitalization amongst people receiving PD were cardiovascular disease (32% of countries), and PD-related infection (23% of countries) (Supplementary Table S10).

Discussion

The aim of ISN-GKHA is to understand, compare and monitor how different countries around the world detect, treat, monitor, and advocate for people with kidney disease.¹³ In this paper, data from the third ISN-GKHA are presented with a focus on the ISN Western Europe region. Compared to the other regional median values, Western Europe is performing well, however there are many opportunities for improvement, specifically related to CKD prevention, surveillance, awareness, and policy implementation.

The median prevalence of CKD across the ISN Western Europe region was 10.6%, slightly higher than the median worldwide at 9.5%. Within the region, there was a two-fold variation between the country with the lowest prevalence, Iceland, and the country with the highest prevalence, Greece. Though caution is required when comparing CKD prevalence due to significant methodological variations in the general population sampling methods and variability in the assessment of kidney

1
2
3 function within studies,⁵⁰ one must still acknowledge that the data are pointing
4
5 towards one in ten Western Europeans having CKD. CKD is associated with adverse
6
7 health outcomes, high cardiovascular mortality, and high healthcare costs. The 2017
8
9 Global Burden of Disease study reported a 41.5% increase in the global all-age
10
11 mortality from CKD between 1990 and 2017.⁵¹ The same study reported that most of
12
13 the burden of CKD was concentrated in the three lowest quintiles of the socio-
14
15 demographic Index. Identifying and treating CKD at the earliest stages will not only
16
17 likely reduce the risk of progression to kidney failure and (cardiovascular) mortality, it
18
19 is also an equity imperative.⁵¹ A recent Kidney Disease Improving Global Outcomes
20
21 (KDIGO) Controversies Conference recommended that individuals with
22
23 hypertension, diabetes, or cardiovascular disease should be screened for CKD.⁵²
24
25 Screening the general population for CKD detection is not currently supported by
26
27 evidence of benefit over costs.^{53,54} We reported high levels of obesity, hypertension,
28
29 and smoking across Western Europe, all of which are known risk factors for the
30
31 development of CKD. Alongside screening for CKD in high-risk populations,
32
33 preventative measures based around tackling CKD risk factors, such as obesity,
34
35 hypertension, and smoking, could be an effective CKD preventative measure.
36
37
38
39
40
41
42
43
44

45 As shown in this study, the ISN Western Europe region has highly developed
46
47 programs to manage the care of the (relatively small) kidney failure population, with
48
49 63% of survey participants reporting that their government recognized kidney failure
50
51 and KRT as a health priority. Programs to manage the care of the much larger non-
52
53 KRT-dependent CKD population are less well developed.⁵⁵ Only 23% felt that CKD
54
55 was a recognized health priority by their country's government, which was almost
56
57 half that of the worldwide opinion (48%). Less than half of the countries surveyed
58
59
60

1
2
3 reported that their country had a national strategy for improving the care of people
4 with CKD with half reporting that this was incorporated into a NCD strategy. Less
5 than a quarter of countries had a national AKI strategy. Even at the European Union
6 (EU) level, CKD was not considered in the 2022 Healthier Together EU NCD
7 Initiative, whereas diabetes, cardiovascular disease, chronic respiratory, mental
8 health, and neurological diseases were.⁵⁶
9
10
11
12
13
14
15
16
17
18

19 Bello et al. reported common barriers to the care of people with non-KRT-
20 dependent CKD in 16 Western European countries.⁵⁵ These were: limited work force
21 capacity, almost a total lack of disease surveillance mechanisms, absence of
22 coordinated CKD care strategies, poor CKD care integration with other NCD control
23 initiatives, and low awareness of the significance of CKD. They suggested potential
24 approaches to improving CKD care by making changes to health systems and policy.
25 These included better models of CKD care, building workforce capacity,
26 incorporating CKD care into (inter)national NCD strategies, and population-based
27 national CKD registries amongst others.⁵⁵
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Compared to the other regions, the ISN Western Europe region has a much
43 larger medical workforce, typically double the number of adult and pediatric
44 nephrologists compared to the world average and higher government healthcare
45 expenditure. Despite this, 59% of survey participants reported the insufficient
46 availability of nephrologists as one of the main barriers to optimal kidney care. Whilst
47 increasing the workforce is the obvious solution here, other mechanisms to
48 streamline and improve the delivery of evidence-based CKD care may also play a
49 role. Taylor et al. recently reported on the contexts, mechanisms, and outcomes
50
51
52
53
54
55
56
57
58
59
60

1
2
3 involved in complex interventions to improve CKD care at the primary and secondary
4 care interface.⁵⁷ Key intervention components identified were automated
5
6 identification of higher-risk individuals in primary care with management advice
7
8 provided to general practitioners, educational support systems, and non-patient-
9
10 facing nephrologist review. These components had the potential to promote clinician
11
12 learning whilst managing individuals with CKD, promote clinician motivation to take
13
14 steps toward evidence-based CKD management, and integrate dynamically with
15
16 existing workflows.⁵⁷
17
18
19
20
21
22
23

24 Just under half of countries reported a lack of political will and enabling
25 policies as a barrier to optimal kidney care in the ISN Western Europe region. Bello
26 et al. reported low awareness of the importance of CKD among the public, policy
27 makers and care providers, perpetuating the limitations in optimal kidney care.⁵⁵
28
29 Surveillance systems such as kidney registries provide data on disease and
30
31 treatment rates which are needed to advocate for, and support the planning,
32
33 delivery, and evaluation of kidney services. The data can also highlight
34
35 discrepancies in available care allowing for the diversion of resources to where they
36
37 are most needed.⁵⁸ This region is in a fortunate position of having dialysis and kidney
38
39 transplant registries available in all countries (except for two microstates).
40
41 Additionally, Europe is fortunate to have a European level registry which then
42
43 collates and presents data allowing for international comparisons and
44
45 benchmarking.² Within the ISN Western Europe region, CKD, AKI, and CKM
46
47 registries were less prevalent, only being available in six (27%), two (9%) and two
48
49 (9%) countries, respectively. Developing CKD and AKI registries will focus attention
50
51 on, and effort towards prevention, whilst data on CKM, be that from patient choice or
52
53
54
55
56
57
58
59
60

1
2
3 limited resources, are necessary to advocate for this vulnerable, high-risk group.
4
5 Though some efforts are being taken to develop these registries,⁵⁹ collecting both
6
7 the right data and accurate data,⁶⁰ especially in the light of limited systematic early
8
9 CKD detection programs, does hamper their development. The ISN's SHARing
10
11 Expertise to support the set-up of Renal Registries (SharE-RR) project provides
12
13 education and support to further establishment and development of kidney registries
14
15 worldwide.⁵⁹
16
17

18
19 Whilst it is clear that the ISN Western Europe region is performing well in all
20
21 aspects of kidney care compared with the other nine ISN regions, improvements are
22
23 certainly possible and welcome. Western European kidney healthcare professionals,
24
25 key stakeholders, and policy makers are called upon to prioritize CKD prevention
26
27 through awareness campaigns, mitigation of CKD risk factors, and the
28
29 implementation of surveillance systems, including registries for AKI and non-KRT
30
31 CKD. These efforts are essential to continue the current positive trend of decreasing
32
33 the incidence of KRT, a condition that is associated, in both children and adults, with
34
35 dire clinical and social consequences as well as massive economic costs.⁶¹ For
36
37 people reaching kidney failure, there should be a focus on patient-centered choice
38
39 for treatments such as CKM and equitable access to home therapies i.e., home HD
40
41 and PD. Collaborative cooperation is essential to minimize disparities between
42
43 Western European countries and ensure high standard of treatment for the CKD
44
45 population living in this region.
46
47
48
49

50
51 There were some limitations to the 2023 ISN-GKHA; these have been
52
53 discussed.¹⁴ However, this work is important for guiding kidney care policy in the ISN
54
55 Western Europe region.
56
57
58
59
60

Role of the Funder/Sponsor

The ISN provided administrative support for the design and implementation of the study and data collection activities. The authors were responsible for data management, analysis, and interpretation, as well as manuscript preparation, review, and approval, and the decision to submit the manuscript for publication.

Disclosure

GA reports personal fees from Baxter, outside the submitted work. MSJ reports grants from Boehringer, Instituto Carlos III, and Marato TV3; personal fees (honoraria) from NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Fresenius, and Traverre Therapeutics, travel support from Traverre and Vifor; patent 202131356; participation on Advisory Boards for NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Bayer, GE Healthcare, and Traverre Therapeutics, outside the submitted work. SA reports personal fees (salary) from The International Society of Nephrology, outside the submitted work. AKB reports other (consultancy and honoraria) from AMGEN Incorporated and Otsuka, other (consultancy) from Bayer and GSK, and grants from Canadian Institute of Health Research and Heart and Stroke Foundation of Canada, outside the submitted work; he is also Associate Editor of the Canadian Journal of Kidney Health and Disease and Co-chair of the ISN-Global Kidney Health Atlas. SD reports personal fees (salary) from The International Society of Nephrology, outside the submitted work. JD reports personal fees (salary) from The International Society of Nephrology, outside the submitted work. VJ reports personal fees from GSK, Astra Zeneca, Baxter Healthcare, Visterra, Biocryst, Chinook, Vera, and Bayer, paid to his institution, outside the submitted

1
2
3 work. DWJ reports consultancy fees, research grants, speaker's honoraria and travel
4 sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees
5 from Astra Zeneca, Bayer, and AWAK, speaker's honoraria from ONO and
6 Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen, outside
7 the submitted work. He is also a current recipient of an Australian National Health
8 and Medical Research Council Leadership Investigator Grant, outside the submitted
9 work. CM reports personal fees (salary) from The International Society of
10 Nephrology, outside the submitted work. MN reports grants and personal fees from
11 KyowaKirin, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Torii, JT, Mitsubishi
12 Tanabe, grants from Takeda and Bayer, and personal fees from Astellas, Akebia,
13 AstraZeneca, and GSK, outside the submitted work. LL reports personal fees from
14 Alexion, Astra Zeneca, Biogen Idec, BMS, GSK, Kezar, Novartis, Pfizer, Roche, and
15 Otsuka, outside the submitted work; and Scientific advisor and investor in Carna
16 Health. All others have nothing to declare.

37 **Acknowledgements**

38
39 This article is published as part of a supplement supported by the
40 International Society of Nephrology (ISN; grant RES0033080 to the University of
41 Alberta). The ISN provided administrative support for the design and implementation
42 of the survey and data collection activities. The authors were responsible for data
43 management, analysis, and interpretation, as well as manuscript preparation, review,
44 and approval, and the decision to submit the manuscript for publication.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The authors appreciate the support from the ISN's Executive Committee,
4 regional leadership, and Affiliated Society leaders at the regional and country levels
5
6 for their help with the ISN-GKHA.
7
8
9

10 11 12 **SUPPLEMENTARY MATERIAL**

13 14 15 **Supplementary File (PDF)**

16
17 **Table S1.** Workforce (specialist physician, doctor, and nurse) prevalences in the ISN
18
19 Western Europe region.
20

21
22 **Table S2.** Healthcare system funding structure for kidney replacement therapy in the
23
24 ISN Western Europe region [n (100%)].
25

26
27 **Table S3.** Availability of in-center hemodialysis, home hemodialysis, and dialysis in
28
29 the ISN Western Europe region [n (100%)].
30

31
32 **Table S4.** Availability of choice-restricted conservative kidney management* in the
33
34 ISN Western Europe region [n (100%)].
35

36
37 **Table S5.** Barriers to optimal kidney care, overall and in the ISN Western Europe
38
39 region [n (100%)].
40

41
42 **Table S6.** National health strategies for non-communicable diseases and CKD-
43
44 specific policies in the ISN Western Europe region [n (100%)].
45

46
47 **Table S7.** Commonest causes of death among people receiving hemodialysis in the
48
49 ISN Western Europe region [n (100%)].
50

51
52 **Table S8.** Commonest causes of death among people receiving peritoneal dialysis in
53
54 the ISN Western Europe region [n (100%)].
55
56
57
58
59
60

1
2
3 **Table S9.** Commonest causes of hospitalization amongst people receiving
4 hemodialysis in the ISN Western Europe region [n (100%)].
5
6
7

8 **Table S10.** Commonest causes of hospitalization amongst people receiving
9 peritoneal dialysis in the ISN Western Europe region [n (100%)].
10
11
12

13 **Figure S1.** Country-level scorecard on the availability of KRT, CKM, funding for
14 medications, registry, advocacy group, nephrologists and nephrology trainees in the
15 ISN Western Europe region in 2019 and 2023.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Kelly DM, Anders HJ, Bello AK, et al. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. *Kidney Int Suppl* (2011). 2021;11(2):e106-e18.
2. Jager KJ, Wanner C. Fifty years of ERA-EDTA Registry-a registry in transition. *Kidney Int Suppl* (2011). 2015;5(1):12-4.
3. Boenink R, Kramer A, Masoud S, et al. International comparison and time trends of first kidney transplant recipient characteristics across Europe: an ERA Registry study. *Nephrol Dial Transplant*. Published online August 31, 2023. doi:10.1093/ndt/gfad189
4. Boenink R, Kramer A, Tuinhout RE, et al. Trends in kidney transplantation rate across Europe: study from the ERA Registry. *Nephrol Dial Transplant*. 2023;38(6):1528-39.
5. Bonthuis M, Cuperus L, Chesnaye NC, et al. Results in the ESPN/ERA-EDTA Registry suggest disparities in access to kidney transplantation but little variation in graft survival of children across Europe. *Kidney Int*. 2020;98(2):464-75.
6. Bonthuis M, Vidal E, Bjerre A, et al. Ten-year trends in epidemiology and outcomes of pediatric kidney replacement therapy in Europe: data from the ESPN/ERA-EDTA Registry. *Pediatr Nephrol*. 2021;36(8):2337-48.
7. Pippias M, Jager KJ, Kramer A, et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. *Nephrol Dial Transplant*. 2016;31(5):831-41.
8. Astley ME, Boenink R, Abd ElHafeez S, et al. The ERA Registry Annual Report 2020: a summary. *Clin Kidney J*. 2023;16(8):1330-54.

- 1
2
3 9. Torreggiani M, Piccoli GB, Moio MR, et al. Choice of the Dialysis Modality:
4 Practical Considerations. *J Clin Med.* 2023;12(9).
5
6
- 7
8 10. Pawlowicz-Szlarska E, Vanholder R, Sever MS, et al. Distribution,
9 preparedness and management of Ukrainian adult refugees on dialysis-an
10 international survey by the Renal Disaster Relief Task Force of the European
11 Renal Association. *Nephrol Dial Transplant.* 2023;38(10):2407-15.
12
13
- 14
15 11. Tuglular S, Luyckx V, Vanholder R, et al. Lessons learned during the war in
16 Ukraine: a report from the Renal Disaster Relief Task Force of the ERA.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11. Tuglular S, Luyckx V, Vanholder R, et al. Lessons learned during the war in
Ukraine: a report from the Renal Disaster Relief Task Force of the ERA.
Nephrol Dial Transplant. 2023;38(9):1960-8.
12. Vanholder R, Agar J, Braks M, et al. The European Green Deal and
nephrology: a call for action by the European Kidney Health Alliance. *Nephrol
Dial Transplant.* 2023;38(5):1080-8.
13. Bello AK, Johnson DW, Feehally J, et al. Global Kidney Health Atlas (GKHA):
design and methods. *Kidney Int Suppl* (2011). 2017;7(2):145-53.
14. Okpechi IG, Bello AK, Levin A, et al. An update on the variability in the
organization and structures of kidney care across world region. (submitted to
Kidney Int Suppl, this issue). 2023.
15. Central Intelligence Agency. The World Factbook. Available at:
<https://www.cia.gov/the-world-factbook/>. Accessed April 8, 2022.
16. The Institute for Health Metrics and Evaluation. Global Health Data Exchange.
Global Expected Health Spending 2019-2050. Available at:
[https://ghdx.healthdata.org/record/ihme-data/global-expected-health-spending-
2019-2050](https://ghdx.healthdata.org/record/ihme-data/global-expected-health-spending-2019-2050). Accessed April 8, 2022.
17. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease
Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019)

- 1
2
3 Results. 2020. Available at: <https://vizhub.healthdata.org/gbd-results/>.
4
5 Accessed April 8, 2022.
6
7
8 18. World Health Organization. Global Health Observatory. Available at:
9
10 <https://www.who.int/data/gho>. Accessed April 8, 2022.
11
12 19. European Renal Association. ERA Registry Annual Report 2019. 2019.
13
14 Available at: [https://www.era-online.org/wp-content/uploads/2022/11/ERA-](https://www.era-online.org/wp-content/uploads/2022/11/ERA-Registry-Annual-Report-2019.pdf)
15
16 [Registry-Annual-Report-2019.pdf](https://www.era-online.org/wp-content/uploads/2022/11/ERA-Registry-Annual-Report-2019.pdf). Accessed April 8, 2022.
17
18
19 20. Finnish Registry for Kidney Diseases Report 2020. Available at:
20
21 [https://www.muma.fi/files/5627/Finnish_Registry_for_Kidney_Diseases_Report](https://www.muma.fi/files/5627/Finnish_Registry_for_Kidney_Diseases_Report_2020.pdf)
22
23 [_2020.pdf](https://www.muma.fi/files/5627/Finnish_Registry_for_Kidney_Diseases_Report_2020.pdf) . Accessed April 8, 2022.
24
25
26 21. Jain AK, Blake P, Cordy P, et al. Global trends in rates of peritoneal dialysis. *J*
27
28 *Am Soc Nephrol*. 2012;23(3):533-544.
29
30
31 22. Nefrovisie, Utrecht, the Netherlands 2021. Renine Registry Annual Report
32
33 2021. Available at: [https://www.nefrovisie.nl/wp-](https://www.nefrovisie.nl/wp-content/uploads/2022/02/Jaarrapportage_Renine_2020_web.pdf)
34
35 [content/uploads/2022/02/Jaarrapportage_Renine_2020_web.pdf](https://www.nefrovisie.nl/wp-content/uploads/2022/02/Jaarrapportage_Renine_2020_web.pdf). Accessed
36
37 April 8, 2022.
38
39
40 23. The Norwegian Renal Registry. Annual Report 2020. Available at:
41
42 https://www.nephro.no/nnr/AARSRAPPORT_NNR_2020.pdf. Accessed April 8,
43
44 2022.
45
46
47 24. The Renal Association. UK Renal Registry 23rd Annual Report. Available at:
48
49 https://ukkidney.org/sites/renal.org/files/23rd_UKRR_ANNUAL_REPORT.pdf.
50
51 Accessed April 8, 2023.
52
53
54 25. United States Renal Data System. 2019 USRDS Annual Data Report:
55
56 Epidemiology of kidney disease in the United States. National Institutes of
57
58 Health, National Institute of Diabetes and Digestive and Kidney Diseases,
59
60

- Bethesda, MD, 2019. Available at: <https://www.niddk.nih.gov/about-niddk/strategic-plans-reports/USRDS/prior-data-reports/2019>. Accessed April 8, 2022.
26. WHO-ONT Global Observatory on Donation and Transplantation. Available at: <http://www.transplant-observatory.org/data-charts-and-tables/>. Accessed April 8, 2022.
27. Cavallo MC, Sepe V, Conte F, et al. Cost-effectiveness of kidney transplantation from DCD in Italy. *Transplant Proc* 2014; 46(10):3289-96.
28. Ferguson TW, Harper GD, Milad JE, et al. Cost of the quanta SC+ hemodialysis system for self-care in the United Kingdom. *Hemodial Int*, 2022; 26(3):287-294.
29. Häckl D, Kossack N, Schoenfelder T. Prävalenz, Kosten der Versorgung und Formen des dialysepflichtigen chronischen Nierenversagens in Deutschland: Vergleich der Dialyseversorgung innerhalb und außerhalb stationärer Pflegeeinrichtungen [Prevalence, Costs of Medical Treatment and Modalities of Dialysis-dependent Chronic Renal Failure in Germany: Comparison of Dialysis Care of Nursing Home Residents and in Outpatient Units]. *Gesundheitswesen* 2021; 83(10):818-28.
30. Haller M, Gutjahr G, Kramar R, et al. Cost-effectiveness analysis of renal replacement therapy in Austria. *Nephrol Dial Transplant*. 2011; 26(9):2988-95.
31. Helanterä I, Isola T, Lehtonen TK, et al. Association of Clinical Factors with the Costs of Kidney Transplantation in the Current Era. *Ann Transplant*. 2019; 24:393-400.

- 1
2
3 32. Jakobsen A, Albrechtsen D, Sødal G, et al. Kostnader ved uremikeromsorg.
4 Hva koster nyretransplantasjon? [Costs of care in uremia. How much does
5 kidney transplantation cost?]. Tidsskr Nor Laegeforen 1990; 110(3):338-41.
6
7
8
9
- 10 33. Jarl J, Desatnik P, Peetz Hansson U, et al. Do kidney transplantations save
11 money? A study using a before-after design and multiple register-based data
12 from Sweden. Clin Kidney J. 2018; 11(2):283-88.
13
14
15
16
- 17 34. Jensen CE, Sørensen P, Petersen KD. In Denmark kidney transplantation is
18 more cost-effective than dialysis. Dan Med J. 2014; 61(3):A4796.
19
20
21
- 22 35. Jürgensen JS, Ikenberg R, Greiner RA, et al. Cost-effectiveness of modern
23 mTOR inhibitor based immunosuppression compared to the standard of care
24 after renal transplantation in Germany. Eur J Health Econ 2015; 16(4):377-90.
25
26
27
- 28 36. Kerr M, Bray B, Medcalf J, et al. Estimating the financial cost of chronic kidney
29 disease to the NHS in England. Nephrol Dial Transplant. 2012; 27 Suppl
30 3(Suppl 3):iii73-80.
31
32
33
34
- 35 37. Li B, Cairns JA, Fotheringham J, et al. Understanding cost of care for patients
36 on renal replacement therapy: looking beyond fixed tariffs. Nephrol Dial
37 Transplant. 2015; 30(10):1726–34.
38
39
40
41
- 42 38. Mohnen SM, van Oosten MJM, Los J, et al. Healthcare costs of patients on
43 different renal replacement modalities - Analysis of Dutch health insurance
44 claims data. PLoS One. 2019; 14(8):e0220800.
45
46
47
48
- 49 39. Roberts G, Holmes J, Williams G, et al. Current costs of dialysis modalities: A
50 comprehensive analysis within the United Kingdom. Perit Dial Int. 2022;
51 42(6):578-84.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40. Rocha MJ, Ferreira S, Martins LS, et al. Cost analysis of renal replacement therapy by transplant in a system of bundled payment of dialysis. *Clin Transplant*. 2012; 26(4):529-31.
 41. Sandoz MS, Ess SM, Keusch GW, et al. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001. *Swiss Med Wkly*. 2004; 134(31-32):448-58.
 42. Van Biesen W, Lameire N, Peeters P, et al. Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease. *Int J Health Care Finance Econ*. 2007; 7(2-3):133-48.
 43. van der Tol A, Lameire N, Morton RL, et al. An International Analysis of Dialysis Services Reimbursement. *Clin J Am Soc Nephrol*. 2019; 14(1):84-93.
 44. Villa G, Rodríguez-Carmona A, Fernández-Ortiz L, et al. Cost analysis of the Spanish renal replacement therapy programme. *Nephrol Dial Transplant*. 2011; 26(11):3709-14.
 45. Zambrowski JJ. Coût de la dialyse [Cost of dialysis in France]. *Nephrol Ther*. 2016; 12 Suppl 1:S95-97.
 46. World Health Organization Global Health Observatory. Health workforce 2021. Available at: <https://www.who.int/data/gho/data/themes/health-workforce>. Accessed April 8, 2022.
 47. Social Progressive Imperative. Global Index: Results. Available at: <https://www.socialprogress.org/index/global/results/>. Accessed October 6, 2023.
 48. Sustainable Development Solutions Network. World Happiness Report. Helliwell JF, Layard R, Sachs J, et al. Published 2023. Available at: <https://worldhappiness.report/ed/2023/>. Accessed October 6, 2023.

- 1
2
3 49. The World Bank. World Development Indicators. The World by Income and
4
5 Region. Available at: [https://datatopics.worldbank.org/world-development-](https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html)
6
7 indicators/the-world-by-income-and-region.html. Accessed April 8, 2022.
8
9
- 10 50. Bruck K, Jager KJ, Dounousi E, et al. Methodology used in studies reporting
11
12 chronic kidney disease prevalence: a systematic literature review. *Nephrol Dial*
13
14 *Transplant.* 2015;30 Suppl 4(Suppl 4):iv6-16.
15
16
- 17 51. GBD Chronic Kidney Disease Collaboration. Global, regional, and national
18
19 burden of chronic kidney disease, 1990-2017: a systematic analysis for the
20
21 Global Burden of Disease Study 2017. *Lancet.* 2020;395(10225):709-733.
22
23
- 24 52. Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early
25
26 identification and intervention of chronic kidney disease: conclusions from a
27
28 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
29
30 Conference. *Kidney Int.* 2021;99(1):34-47.
31
32
- 33 53. Jain V, Sinha S, Shaw C, et al. Re-evaluating national screening for chronic
34
35 kidney disease in the UK. *BMJ.* 2023;382:e074265.
36
37
- 38 54. Bochud M. On the rationale of population screening for chronic kidney disease:
39
40 a public health perspective. *Public Health Rev.* 2015;36:11.
41
42
- 43 55. Bello AK, Levin A, Manns BJ, et al. Effective CKD care in European countries:
44
45 challenges and opportunities for health policy. *Am J Kidney Dis.* 2015;65(1):15-
46
47 25.
48
- 49 56. Directorate-General for Health and Food Safety. EU Non-communicable
50
51 diseases (NCD) Initiative: Guidance document. Published 2022. Available at:
52
53 [https://health.ec.europa.eu/publications/eu-non-communicable-diseases-ncds-](https://health.ec.europa.eu/publications/eu-non-communicable-diseases-ncds-initiative-guidance-document_en)
54
55 initiative-guidance-document_en. Accessed October 6, 2023.
56
57
58
59
60

- 1
2
3 57. Taylor DM, Nimmo AM, Caskey FJ, et al. Complex Interventions Across
4 Primary and Secondary Care to Optimize Population Kidney Health: A
5 Systematic Review and Realist Synthesis to Understand Contexts,
6 Mechanisms, and Outcomes. Clin J Am Soc Nephrol. 2023;18(5):563-72.
7
8
9
- 10
11
12 58. Alwan A, Maclean DR, Riley LM, et al. Monitoring and surveillance of chronic
13 non-communicable diseases: progress and capacity in high-burden countries.
14 Lancet. 2010;376(9755):1861-8.
15
16
17
- 18
19 59. Hole BD, Evans KM, Pyart R, et al. International collaborative efforts to establish
20 kidney health surveillance systems. Kidney Int. 2020;98(4):812-6.
21
22
23
- 24 60. Nistor I, Bolignano D, Haller MC, et al. Why creating standardized core
25 outcome sets for chronic kidney disease will improve clinical practice. Nephrol
26 Dial Transplant. 2017;32(8):1268-73.
27
28
29
- 30 61. Kidney Research UK. Kidney disease: A UK public health emergency. The
31 health economics of kidney disease to 2033. Published 2023. Available at:
32 [https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-](https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf)
33 [Kidney-Disease-full-report_accessible.pdf](https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf). Accessed October 6, 2023.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Tables

Table 1. Demographics and health finance in the ISN Western Europe region.^{15,16}

Country	Area (sq km)	Total population (2022)	GDP (PPP) (\$ billion)	Total health expenditures (% of GDP)	Total Health Spending per person*	Government Health Spending per person*	Out-of-pocket Health Spending per person*
Overall, median [IQR]	130,483,015	7,802,702,984	133.8 [39.7 - 545.0]	6.2 [4.3-8.2]	353 [76 -1270]	216 [23 - 908]	92 [29 - 273]
ISN Western Europe region, median [IQR]	3,801,668	439,465,153	529.3 [351.7 - 1523.9]	9.5 [8.2 - 10.5]	5088 [3259 - 5851]	3798 [2470 - 4701]	637 [589 - 800]
Andorra	468	85,560	3.3	6.7	2,875	1,993	358
Austria	83,871	8,913,088	523.3	10.4	5,721	4,361	907
Belgium	30,528	11,847,338	682.9	10.7	5,088	3,998	848
Denmark	43,094	5,920,767	378.6	10	6,300	5,392	767
Finland	357,022	5,601,547	304.8	9.2	4,553	3,666	755
France	643,801	68,305,148	3,424.2	11.1	4,838	3,629	403
Germany	357,022	84,316,622	4,815.5	11.7	5,838	4,701	627
Greece	131,957	10,533,871	333.7	7.8	1,599	909	514
Iceland	572	357,603	21.5	8.6	5,670	4,779	800
Ireland	70,723	5,275,004	535.3	6.7	6,128	4,690	637
Israel	20,770	8,914,885	409.4	7.5	3,259	2,241	627
Italy	2,586	61,095,551	2,713.3	8.7	3,205	2,491	640
Liechtenstein	160	39,711	5.0	NA	-	-	-
Luxembourg	2,586	650,364	86.1	5.4	6,782	5,976	609
Malta	316	464,186	25.2	8.2	3,553	2,470	1,013
Netherlands	41,543	17,400,824	1,118.1	10.1	5,621	3,798	535
Norway	323,802	5,553,840	428.3	10.5	7,254	6,300	929
Portugal	450,295	10,242,081	369.6	9.5	2,230	1,446	589
Spain	505,370	47,163,418	1,929.8	9.1	3,001	2,246	556
Sweden	450,295	10,483,647	617.9	10.9	5,851	5,046	740

Switzerland	41,277	8,508,698	672.5	11.3	9,801	3,290	2,532
United Kingdom	243,610	67,791,400	3,344.5	10.2	4,903	4,093	625

ISN, International Society of Nephrology; sq, square; km, kilometers; GDP, Gross Domestic Product; PPP, Purchasing Power Parity; IQR, Interquartile Range

*US\$ 2021

Table 2. Burden of CKD and risk factors in the ISN Western Europe region.¹⁷⁻¹⁸

	CKD Prevalence % (95% CI)	Death attributed to CKD % (95% CI)	DALYS attributed to CKD % (95% CI)	Obesity % (95% CI)	Increased BP % (95% CI)	Smoking % (95% CI)
Overall, median [IQR]	9.54 [5.87 - 11.73]	2.44 [1.58 - 3.88]	1.47 [1.07 - 2.30]	21.9 [7.8 - 26.6]	24.8 [20.8 - 28.5]	13.1 [7.8 - 20.1]
ISN Western Europe region, median [IQR]	10.63 [9.59 - 11.57]	2.59 [2.11 - 3.42]	1.32 [1.09 - 1.59]	24.5 [23.1 - 26.9]	19.4 [18.7 - 20.6]	18.8 [17.8 - 21.2]
Andorra	9.17 (8.48 - 9.80)	2.59 (2.19 - 2.94)	1.19 (1.01 - 1.36)	28.0 (22.0 - 34.0)	18.7 (13.3 - 24.8)	20.6 (18.1 - 23.0)
Austria	11.57 (10.73 - 12.38)	4.08 (3.47 - 4.51)	1.85 (1.61 - 2.09)	21.9 (17.5 - 26.8)	21.0 (15.7 - 27.1)	25.2 (22.8 - 27.8)
Belgium	11.00 (10.28 - 11.70)	2.6 (2.2 - 2.92)	1.33 (1.15 - 1.49)	24.5 (20.7 - 28.5)	17.5 (12.9 - 23.0)	18.7 (17.0 - 20.4)
Denmark	10.63 (9.86 - 11.37)	2.05 (1.77 - 2.26)	1.23 (1.08 - 1.38)	21.3 (17.5 - 25.3)	20.6 (15.9 - 25.7)	17.5 (16.0 - 19.1)
Finland	10.22 (9.50 - 10.89)	1.26 (1.06 - 1.4)	0.77 (0.68 - 0.86)	24.9 (21.2 - 28.7)	19.4 (15.2 - 24.1)	16.8 (15.2 - 18.6)
France	10.49 (9.77 - 11.28)	2.11 (1.71 - 2.42)	1.09 (0.94 - 1.24)	23.2 (18.8 - 27.8)	22.0 (16.6 - 27.8)	21.4 (19.3 - 23.4)
Germany	12.27 (11.57 - 12.96)	3.67 (3.15 - 4.06)	1.8 (1.57 - 2.02)	25.7 (21.9 - 29.8)	19.9 (14.7 - 25.1)	21.2 (19.2 - 23.3)
Greece	14.67 (12.73 - 16.91)	3.58 (3.13 - 3.97)	2.1 (1.85 - 2.36)	27.4 (22.5 - 32.7)	19.1 (13.8 - 25.3)	31.2 (28.9 - 33.5)
Iceland	7.99 (7.44 - 8.56)	1.58 (1.32 - 1.78)	0.81 (0.7 - 0.92)	23.1 (19.1 - 27.4)	19.7 (14.1 - 25.9)	14.7 (12.9 - 16.5)
Ireland	9.59 (9.17 - 10.04)	2.16 (1.85 - 2.43)	1.08 (0.94 - 1.23)	26.9 (22.3 - 31.7)	19.7 (14.7 - 25.3)	21.6 (19.2 - 24.2)
Israel	8.45 (7.86 - 9.05)	5.77 (4.95 - 6.37)	2.45 (2.1 - 2.83)	26.7 (21.9 - 31.6)	16.6 (11.7 - 22.4)	17.8 (15.9 - 20.0)
Italy	12.17 (11.30 - 13.06)	2.57 (2.16 - 2.81)	1.39 (1.21 - 1.55)	22.9 (19.3 - 26.8)	21.2 (16.2 - 26.3)	19.4 (17.7 - 21.4)
Liechtenstein	-	-	-	-	-	-
Luxembourg	9.84 (9.16 - 10.53)	2.87 (2.43 - 3.22)	1.32 (1.14 - 1.49)	24.2 (19.4 - 29.4)	21.9 (16.3 - 27.9)	20.9 (18.4 - 23.6)
Malta	11.91 (11.03 - 12.77)	2.79 (2.39 - 3.12)	1.59 (1.38 - 1.8)	31.0 (25.1 - 37.0)	19.4 (13.8 - 25.5)	18.8 (16.6 - 20.9)
Netherlands	11.26 (10.47 - 12.05)	2.41 (2.06 - 2.69)	1.24 (1.08 - 1.4)	23.1 (19.3 - 27.0)	18.7 (14.4 - 23.7)	17.9 (16.2 - 19.5)
Norway	8.82 (8.20 - 9.41)	1.87 (1.61 - 2.03)	0.97 (0.84 - 1.08)	25.0 (20.9 - 29.2)	19.7 (14.7 - 25.0)	15.3 (13.6 - 17.2)
Portugal	11.58 (10.63 - 12.55)	3.5 (2.98 - 3.87)	1.8 (1.56 - 2.04)	23.2 (18.8 - 27.8)	24.4 (18.2 - 31.2)	17.8 (15.9 - 19.8)
Spain	10.33 (9.57 - 11.10)	3.42 (2.82 - 3.9)	1.52 (1.3 - 1.74)	27.1 (23.2 - 31.1)	19.2 (14.5 - 24.6)	21.8 (19.7 - 24.0)
Sweden	11.14 (10.30 - 11.95)	2.13 (1.8 - 2.35)	1.13 (0.98 - 1.28)	22.1 (18.3 - 26.0)	19.3 (14.7 - 24.3)	11.4 (10.7 - 12.2)

Switzerland	11.44 (10.63 - 12.20)	3.18 (2.63 - 3.62)	1.36 (1.15 - 1.54)	21.2 (17.3 - 25.3)	18.0 (13.5 - 23.2)	19.1 (17.1 - 21.3)
United Kingdom	9.07 (8.43 - 9.72)	1.25 (1.1 - 1.34)	0.82 (0.72 - 0.9)	29.5 (26.6 - 32.5)	15.2 (12.2 - 18.3)	18.7 (17.0 - 20.4)

ISN, International Society of Nephrology; CKD, chronic kidney disease; CL, confidence interval; BP, blood pressure; IQR, Interquartile Range; DALYs, disability-adjusted life years
All presented as percentages with 95% confidence intervals (95%CI).

Table 3. Kidney replacement therapy statistics in the ISN Western Europe region.¹⁹⁻²⁶

Country	Treated KF		Chronic dialysis (HD+PD)		Chronic Hemodialysis		Chronic PD		Kidney Transplants Overall		Incidence of deceased donor transplants	Incidence of living donor transplants	Incidence of pre-emptive transplants
	Incidence	Prevalence	Incidence	Prevalence	Incidence	Prevalence	Incidence	Prevalence	Incidence	Prevalence			
Andorra	-	-	-	-	-	-	-	-	-	-	-	-	-
Austria	135	1044	128.8	536.2	118.2	495.8	10.6	40.4	34	507.1	29.33	4.67	6.7
Belgium	197	1337	194.2	766.15	175.85	708.65	18.35	57.5	35.95	569.65	30.86	5.09	2.9
Denmark	108	952	97.9	434	61.8	346.8	36.1	87.2	43.45	517.7	31.72	11.72	10
Finland	94	957	91.7	361	69.2	306.8	22.5	54.2	48.73	601	40.36	8.36	4.3
France	170	1376	162.7	746.5	146.1	700.7	16.6	45.8	49.72	622.3	42.05	7.68	7.1
Germany	-	1114	-	808	-	768.1	-	38.8	23.74	-	18.08	5.66	-
Greece	269	1413	267.8	1164.4	255.1	1100.5	12.7	63.9	16.54	248.9	7.98	8.56	1.1
Iceland	108	810	91.5	241.3	69.3	196.9	22.2	44.4	30	565.8	23.33	6.67	13.9
Ireland	88	979	-	445	-	401.39	-	39.16	27.8	533	20.8	7	-
Israel	198	755	-	756	-	698.32	-	62.35	54.09	492	16.93	37.16	-
Italy	165	1276	-	800	-	701.8	-	89.32	31.52	476	26.83	4.69	-
Liechtenstein	-	-	-	-	-	-	-	-	-	-	-	-	-
Luxembourg	-	522	-	87	-	596.7	-	4.7	12	-	12	0	-
Malta	-	-	-	-	-	-	-	-	7.5	-	7.5	0	-
Netherlands	106	1034	103.4	379	83.1	322.7	20.3	56.3	53.26	695.2	26.98	26.28	16.8
Norway	100	1014.5	101.6	317.3	72.2	252.2	29.4	65.1	44.7	686.4	33.52	10.93	11.8
Portugal	260	2008	-	1302	-	871.3	-	48.1	42.06	707	38.53	3.53	-
Spain	152	1368	139.2	599.6	114.7	531.4	24.5	68.2	63.17	751.2	56.25	6.92	6.8
Sweden	113	996	103.5	401.2	68.4	316.1	35.1	85.1	43.63	594.7	32.06	11.57	9.7
Switzerland	99	968	93.7	447.8	80.8	408.5	12.9	39.3	41.61	519.2	27.59	14.02	5.1
United Kingdom	151	1293	102.9	414.8	81.5	489	21.4	69	42.77	735	32.02	10.75	12.8

ISN, International Society of Nephrology; KF, kidney failure; HD, hemodialysis; PD, peritoneal dialysis

Table 4. Annual cost of kidney replacement therapy in the ISN Western European region.²⁷⁻⁴⁵

	Hemodialysis	Peritoneal dialysis	Kidney Transplant (First year)	Kidney Transplant (later years)	HD/PD ratio
Austria	-	-	-	-	-
Belgium	60,853	29,147	76,552	22,635	2.09
Denmark	71,318	63,935	35,737	9,920	1.12
Finland	65,842	31,057	27,394	578	2.12
France	67,830	37,269	71,627	14,480	1.82
Germany	48,256	35,465	126,993	29,533	1.36
Greece	79,499	32,622	76,629	19,924	2.44
Iceland	24,419	27,206	-	-	0.90
Ireland	81,031	18,959	-	-	4.27
Israel	66,861	40,809	-	-	1.64
Italy	62,082	72,627	-	-	0.85
Liechtenstein	32,029	21,076	96,430	14,091	1.52
Luxembourg	-	-	-	-	-
Malta	-	-	-	-	-
Netherlands	-	-	-	-	-
Norway	99,419	66,655	118,595	41,254	1.49
Portugal	71,791	50,534	41,108	25,242	1.42
Spain	30,361	30,361	116,952	12,379	1.00
Sweden	26,937	59,854	64,822	10,630	0.45
Switzerland	80,520	-	94,144	18,054	-
United Kingdom	94,085	83,070	19,255	-	1.13

ISN, International Society of Nephrology; HD, hemodialysis; PD, peritoneal dialysis

Costs in \$US in 2021

Table 5. Funding structures for kidney care in the ISN Western Europe region.

Country	Acute Kidney Injury			CKD no dialysis				Dialysis					Transplantation					
	Publicly funded by govt; free at the point of delivery	Solely private through health insurance providers	Multiple systems	Publicly funded by govt; free at the point of delivery	Publicly funded by govt but with some fees at the point of delivery	Mix of public and private funding systems	Solely private through health insurance providers	Multiple systems	Publicly funded by govt; free at the point of delivery	Publicly funded by govt but with some fees at the point of delivery	Mix of public and private funding systems	Solely private through health insurance providers	Multiple systems	Publicly funded by govt; free at the point of delivery	Publicly funded by govt but with some fees at the point of delivery	Mix of public and private funding systems	Solely private through health insurance providers	Multiple systems
Andorra			X					X									X	
Austria	X			X					X				X					X
Belgium	X				X					X				X				
Denmark	X			X					X				X					X
Finland	X				X					X				X				
France	X					X					X				X			
Germany	X				X					X				X				
Greece	X				X				X				X					X
Iceland	X				X					X				X				X
Ireland	X					X					X				X			
Israel	X				X				X				X					X
Italy	X			X					X				X					X
Liechtenstein		X					X					X			X			
Luxembourg	X				X					X				X				X
Malta	X			X					X				X					X
Netherlands	X						X					X			X			
Norway	X				X					X				X				
Portugal	X				X					X				X				
Spain	X				X					X				X				
Sweden	X				X					X				X				
Switzerland	X						X		X						X			
United Kingdom	X				X					X				X				

CKD, chronic kidney disease; ISN, International Society of Nephrology

Table 6. Availability of KRT centers and nephrology workforce in the ISN Western Europe region.

	Chronic HD Centers PMP	Chronic PD Centers PMP	Transplant Centers PMP	Nephrologists PMP	Nephrology trainees PMP
Andorra	11.69	11.69		0.00	0.00
Austria	5.61	1.12	0.45	33.66	5.61
Belgium	8.44	-	0.59	21.10	4.22
Denmark	2.70	2.70	0.51	25.33	4.05
Finland	5.18	3.93	0.18	19.64	8.93
France	9.31	2.20	0.69	17.57	5.86
Germany	8.66	2.73	0.55	27.01	0.59
Greece	18.99	2.85	0.57	36.07	9.49
Iceland	13.98	2.80	2.80	30.76	0.00
Ireland	2.46	1.90	0.19	11.75	9.48
Israel	7.74	2.24	0.67	24.68	3.93
Italy	9.00	3.27	0.65	-	49.10
Liechtenstein	25.18	25.18	NA	100.73	0.00
Luxembourg	7.69	1.54	NA	12.30	6.15
Malta	4.31	2.15	2.15	-	17.23
Netherlands	3.62	3.74	0.46	15.17	2.30
Norway	4.50	4.68	0.18	27.37	9.00
Portugal	12.89	1.95	0.78	34.17	14.65
Spain	4.24	1.70	0.85	53.01	10.60
Sweden	6.68	5.25	0.38	23.85	6.68
Switzerland	10.58	7.05	0.12	41.13	5.88
United Kingdom	1.00	1.00	0.34	12.13	6.15

KRT, kidney replacement therapy; ISN, International Society of Nephrology; HD, hemodialysis; PD, peritoneal dialysis; pmp, per million population

Table 7. Availability of CKD, dialysis, kidney transplant, AKI, and CKM registries in the ISN Western Europe region.

Country	CKD	Dialysis	Transplant	AKI	CKM
Andorra					
Austria		X	X		
Belgium		X	X		
Denmark		X	X		
Finland		X	X		
France	X	X	X		
Germany		X	X		
Greece		X	X		
Iceland	X	X	X		X
Ireland		X	X		
Israel		X	X		
Italy		X	X		
Liechtenstein					
Luxembourg	X	X	X		
Malta		X	X		
Netherlands		X	X		
Norway	X	X	X		
Portugal		X	X		
Spain		X	X		
Sweden	X	X	X	X	X
Switzerland		X	X		
United Kingdom	X	X	X	X	

ISN, International Society of Nephrology; CKD, chronic kidney disease; AKI, acute kidney injury; CKM, conservative kidney management

Figure Legends

Figure 1. Countries of the ISN Western Europe region.

ISN, International Society of Nephrology

Figure 2. Availability of KRT centres in ISN Western Europe region: chronic hemodialysis (A), peritoneal dialysis (B), and kidney transplantation (C).

ISN, International Society of Nephrology

Figure 3. Workforce shortages for medical kidney care in the ISN Western Europe region.

1
2
3 ISN, International Society of Nephrology; HD, hemodialysis; PD, peritoneal dialysis
4
5
6
7

8 **Appendix 1. Regional Board and GKHA Team Authors**

9

10 Atefeh Amouzegar, Division of Nephrology, Department of Medicine, Firoozgar
11
12 Clinical Research Development Center, Iran University of Medical Sciences,
13
14 Tehran, Iran
15
16

17 Hans-Joachim Anders, Department of Medicine IV, Hospital of Ludwig Maximilian
18
19 University of Munich, Munich, Germany
20
21

22 Jyoti Baharani, Department of Renal Medicine, University Hospitals Birmingham,
23
24 Heartlands Hospital, Birmingham, United Kingdom
25
26

27 Debasish Banerjee, Renal and Transplantation Unit, St. George's University
28
29 Hospitals National Health Service Foundation Trust, Molecular and Clinical
30
31 Sciences Research Institute, St. George's University of London, London, UK
32
33

34 Boris Bikbov, Scientific-Tools.Org, Global Health Department, Bergamo, Italy
35
36

37 Edwina A. Brown, Imperial College Renal and Transplant Center, Hammersmith
38
39 Hospital, London, UK
40
41

42 Yeoungjee Cho, Department of Kidney and Transplant Services, Princess Alexandra
43
44 Hospital, Brisbane, Queensland, Australia; Australasian Kidney Trials Network
45
46 at the University of Queensland, Australia
47
48
49

50 Kathleen Claes, Department of Nephrology, Dialysis, and Renal Transplantation,
51
52 University Hospitals Leuven, Leuven, Belgium; Department of Microbiology,
53
54 Immunology, and Transplantation, Nephrology and Renal Transplantation
55
56 Research Group, KU Leuven, Leuven, Belgium
57
58
59
60

1
2
3 Naomi Clyne, Department of Nephrology, Clinical Sciences Lund, Faculty of
4
5 Medicine, Skåne University Hospital and Lund University, Lund, Sweden
6
7

8 M. Razeen Davids, Division of Nephrology, Department of Medicine, Stellenbosch
9
10 University and Tygerberg Hospital, Cape Town, South Africa
11
12

13 Sara N. Davison, Division of Nephrology and Immunology, University of Alberta
14
15 Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada
16
17

18 Hassane M. Diongole, Division of Nephrology, Department of Medicine, National
19
20 Hospital Zinder, Zinder, Niger; Faculty of Health Sciences, University of Zinder,
21
22 Zinder, Niger
23
24

25 Smita Divyaveer, Department of Nephrology, Postgraduate Institute of Medical
26
27 Education and Research, Chandigarh, India
28
29

30 Gavin Dreyer, Department of Nephrology, Barts Health NHS Trust, London, UK
31
32

33 Jan Dudley, Department of Paediatric Nephrology, Bristol Royal Hospital for
34
35 Children, Bristol, United Kingdom
36
37

38 Udeme E. Ekrikpo, Department of Internal Medicine, University of Uyo/University of
39
40 Uyo Teaching Hospital, Uyo, Nigeria
41
42
43

44 Isabelle Ethier, Division of Nephrology, Centre Hospitalier de l'Université de
45
46 Montréal, Montréal, Québec, Canada; Health Innovation and Evaluation hub,
47
48 Centre de Recherche du Centre Hospitalier de l'Université de Montréal,
49
50 Montréal, Québec, Canada
51
52
53

54 Rhys D. R. Evans, University College London Department of Renal Medicine, Royal
55
56 Free Hospital, London, UK
57
58
59
60

1
2
3 Stanley L. S. Fan, Department of Renal Medicine and Transplantation, Barts Health
4
5 NHS Trust, London, UK
6
7

8 Winston Wing-Shing Fung, Department of Medicine & Therapeutics, Prince of Wales
9
10 Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
11
12

13 Maurizio Gallieni, Nephrology and Dialysis Unit ASST Fatebenefratelli Sacco,
14
15 Milano, Italy; Specialty School of Nephrology, Department of Biomedical and
16
17 Clinical Sciences, University of Milano, Italy
18
19

20 Anukul Ghimire, Division of Nephrology, Department of Medicine, University of
21
22 Calgary, Calgary, Alberta, Canada
23
24

25 Ghenette Houston, Division of Nephrology and Immunology, Faculty of Medicine and
26
27 Dentistry, University of Alberta, Edmonton, Alberta, Canada
28
29

30 Htay Htay, Department of Renal Medicine, Singapore General Hospital, Singapore,
31
32 Singapore; Duke-NUS Medical School, Singapore, Singapore
33
34
35

36 Kwaifa Salihu Ibrahim, Nephrology Unit, Department of Medicine, Wuse District
37
38 Hospital, Abuja, Nigeria; Department of Internal Medicine, College of Health
39
40 Sciences, Nile University, Federal Capital Territory, Abuja, Nigeria
41
42
43

44 Georgina Irish, Australia and New Zealand Dialysis and Transplant (ANZDATA)
45
46 Registry, South Australia Health and Medical Research Institute, South
47
48 Australia, Australia; Faculty of Health and Medical Sciences, University of
49
50 Adelaide, South Australia, Australia; Central and Northern Adelaide Renal and
51
52 Transplantation Service, Royal Adelaide Hospital, South Australia Health,
53
54 South Australia, Australia
55
56
57
58
59
60

1
2
3 Kailash Jindal, Division of Nephrology and Immunology, Faculty of Medicine and
4
5 Dentistry, University of Alberta, Edmonton, Alberta, Canada
6
7

8 Arif Khwaja, Sheffield Kidney Institute, Northern General Hospital, Sheffield, UK
9

10
11 Rowena Lalji, Centre for Kidney Disease Research, University of Queensland,
12
13 Brisbane, Queensland, Australia; Department of Nephrology, Queensland
14
15 Children's Hospital, Brisbane, Queensland, Australia; Metro South and
16
17 Integrated Nephrology and Transplant Services (MINTS), Princess Alexandra
18
19 Hospital, Brisbane, Queensland, Australia
20
21
22

23 Vassilios Liakopoulos, 2nd Department of Nephrology, AHEPA University Hospital,
24
25 Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
26
27

28
29 Valerie A. Luyckx, Department of Public and Global Health, Epidemiology,
30
31 Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland;
32
33 Renal Division, Brigham and Women's Hospital, Harvard Medical School,
34
35 Boston, Massachusetts, USA; Department of Paediatrics and Child Health,
36
37 University of Cape Town, Cape Town, South Africa
38
39

40
41 Manuel Macia, Department of Nephrology, Hospital Universitario Ntra Sra de
42
43 Candelaria, Santa Cruz de Tenerife, Spain
44
45

46 Hans Peter Marti, Division of Nephrology, Haukeland University Hospital and
47
48 University of Bergen, Bergen, Norway
49
50

51 Piergiorgio Messa, Department of Nephrology, Dialysis and Kidney Transplants,
52
53 IRCCS Ca' Granda Foundation Maggiore Policlinico Hospital, Milan, Italy
54
55

56 Thomas F. Müller, Clinic of Nephrology, University Spital Zürich, Zurich, Switzerland
57
58

59 Aisha M. Nalado, Department of Medicine, Bayero University Kano, Kano, Nigeria
60

1
2
3 Brendon L. Neuen, Kidney Trials Unit, Royal North Shore Hospital, Sydney, New
4
5 South Wales, Australia; The George Institute for Global Health, Sydney, New
6
7 South Wales, Australia
8
9

10 Dorothea Nitsch, Department of Non-communicable Disease Epidemiology, London
11
12 School of Hygiene & Tropical Medicine, London, England, UK
13
14
15

16 Fernando Nolasco, Department of Nephrology, Nova Medical School, Universidade
17
18 Nova de Lisboa, Lisboa, Portugal
19
20

21 Rainer Oberbauer, Division of Nephrology and Dialysis, Department of Internal
22
23 Medicine III, Medical University of Vienna, Vienna, Austria
24
25

26 Mohamed A Osman, Department of Family Medicine, University of Ottawa, Ottawa,
27
28 Ontario, Canada
29
30

31 Aikaterini Papagianni, School of Medicine, Aristotle University of Thessaloniki,
32
33 Thessaloniki, Greece
34
35

36 Anna Petrova, Department of Propaedeutics of Internal Medicine, Bohomolets
37
38 National Medical University, Kyiv, Ukraine; Department of Nephrology, "Diavita
39
40 Institute," Kyiv, Ukraine
41
42
43

44 Giorgina Barbara Piccoli, Nephrology, Centre Hospitalier Le Mans, Le Mans, France
45
46

47 Liam Plant, Department of Renal Medicine, Cork University Hospital and University
48
49 College Cork, Cork, Ireland
50
51

52 Giuseppe Remuzzi, Mario Negri Institute for Pharmacological Research IRCCS,
53
54 Milan, Italy
55
56
57
58
59
60

1
2
3 Parnian Riaz, Division of Nephrology, Department of Medicine, McMaster University,
4
5 Hamilton, Ontario, Canada
6
7

8 Joris J. Roelofs, Department of Pathology, Amsterdam University Medical Center,
9
10 Amsterdam, The Netherlands
11
12

13 Michael Rudnicki, Department of Internal Medicine IV – Nephrology and
14
15 Hypertension, Medical University Innsbruck, Innsbruck, Austria
16
17

18 Syed Saad, Division of Nephrology and Immunology, Faculty of Medicine and
19
20 Dentistry, University of Alberta, Edmonton, Alberta, Canada
21
22

23 Aminu Muhammad Sakajiki, Department of Medicine, Usmanu Danfodiyo University
24
25 and Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria
26
27

28 Johannes B. Scheppach, Department of Nephrology and Medical Intensive Care,
29
30 Charité – Universitätsmedizin Berlin, Berlin, Germany
31
32

33 Emily See, Royal Melbourne Hospital and Royal Children's Hospital, Melbourne,
34
35 Australia; Department of Critical Care, University of Melbourne, Melbourne,
36
37 Australia
38
39

40 Rukshana Shroff, Paediatric Renal Unit, University College London Great Ormond
41
42 Street Hospital and Institute of Child Health, London, United Kingdom
43
44

45 Marit D. Solbu, Section of Nephrology, University Hospital of North Norway, Tromsø,
46
47 Norway; Metabolic and Renal Research Group, UiT The Arctic University of
48
49 Norway, Tromsø, Norway
50
51
52

53 Stephen M. Sozio, Department of Medicine, Johns Hopkins School of Medicine,
54
55 Baltimore, Maryland, USA; Department of Epidemiology, Johns Hopkins
56
57 Bloomberg School of Public Health, Baltimore, Maryland, USA
58
59
60

1
2
3 Giovanni FM Strippoli, Division of Nephrology, Department of Precision and
4
5 Regenerative Medicine and Ionian Area (DiMePre-J), University of Bari, Bari,
6
7 Italy
8
9

10 Maarten W. Taal, Department of Renal Medicine, Royal Derby Hospital, Derby, UK;
11
12 Centre for Kidney Research and Innovation, School of Medicine, University of
13
14 Nottingham, Nottingham, UK
15
16

17
18 James Tataw Ashu, Department of Internal Medicine and Nephrology, Moutier
19
20 hospital, Moutier, Canton of Berne, Switzerland; Department of Medicine,
21
22 Service of Nephrology and Hypertension, Geneva University Hospitals, Canton
23
24 of Geneva, Switzerland
25
26

27
28 Sophanny Tiv, Division of Nephrology and Immunology, Faculty of Medicine and
29
30 Dentistry, University of Alberta, Edmonton, Alberta, Canada
31
32

33 Somkanya Tungsanga, Division of Nephrology and Immunology, Faculty of Medicine
34
35 and Dentistry, University of Alberta, Edmonton, Alberta, Canada; Division of
36
37 General Internal Medicine-Nephrology, Department of Medicine, Faculty of
38
39 Medicine, Chulalongkorn University, Bangkok, Thailand
40
41

42
43 Jeroen B. van der Net, Department of Internal Medicine, Albert Schweitzer Hospital,
44
45 Dordrecht, the Netherlands
46
47

48 Raymond C. Vanholder, Nephrology Section, Department of Internal Medicine and
49
50 Pediatrics, University Hospital, Ghent, Belgium; European Kidney Health
51
52 Alliance (EKHA), Brussels, Belgium
53
54

55
56 Andrea Viecelli, Department of Kidney and Transplant Services, Division of
57
58 Medicine, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia;
59
60

1
2
3 University of Queensland, Queensland, Australia; Australasian Kidney Trials
4
5 Network at the University of Queensland, Australia
6
7

8 Katie Vinen, Department of Renal Medicine, King's College Hospital, Denmark Hill,
9
10 London, United Kingdom
11
12

13 Bruno Vogt, Department of Nephrology, Hypertension and Clinical Pharmacology,
14
15 Bern University Hospital, Bern, Switzerland
16
17

18 Marina Wainstein, Faculty of Medicine, University of Queensland, Brisbane,
19
20 Queensland, Australia; West Moreton Kidney Health Service, Ipswich Hospital,
21
22 Brisbane, Queensland, Australia
23
24

25 Talia Weinstein, Department of Medicine, Tel Aviv University, Tel Aviv, Israel
26
27

28 David C. Wheeler, Department of Renal Medicine, University College London,
29
30 London
31
32

33 Emily K. Yeung, Department of Nephrology, Monash Health, Clayton, Victoria,
34
35 Australia
36
37

38 Deenaz Zaidi, Division of Nephrology and Immunology, Faculty of Medicine and
39
40 Dentistry, University of Alberta, Edmonton, Alberta, Canada
41
42
43
44
45
46

47 **Regional Board and GKHA Team Author Disclosures**

48 HJA reports personal fees from GSK, Novartis, Bayer, AstraZeneca, Boehringer-
49
50 Ingelheim, Roche, Aptarion, and Otsuka, outside the submitted work. DB reports
51
52 grants from AstraZeneca ESR, speaker fees from CSL Vifor and Bayer, outside the
53
54 submitted work. EAB reports grants from Kidney Research UK, personal fees from
55
56 Baxter Healthcare, Fresenius Medical Care, and Vifor, outside the submitted work.
57
58
59
60

1
2
3 YC reports grants and other from Baxter Healthcare, outside the submitted work. KC
4 reports other from Alexion, other from Astra Zeneca, other from Astellas, other from
5 Vifor Pharma, other from Fresenius Kabi, other from Sanofi, non-financial support
6 from GSK, outside the submitted work. MRD reports personal fees (consultancy)
7 from National Renal Care, outside the submitted work, and is the Chair of the African
8 Renal Registry and Co-chair of the South African Renal Registry. SND reports
9 research funding from Canadian Institutes of Health Research, Alberta Innovates,
10 and Alberta Health services. GD reports personal fees (consulting) from Boehringer
11 Ingelheim, outside the submitted work. IE reports grants from Fonds de Recherche
12 du Québec - Santé, outside the submitted work. HH reports personal fees from
13 AWAK technology and Baxter Healthcare, and non-financial support from Mologic
14 company, outside the submitted work. VL reports personal fees from Astra Zeneca,
15 Sanofi, GSK, Alektor, Menarini, Astellas, and grants from Baxter healthcare, outside
16 the submitted work. VAL reports royalties from Elsevier, consulting fees from the
17 World Health Organization, travel support from the European Renal Association and
18 International Society of Nephrology, and leadership role in Advocacy Working Group
19 of the International Society of Nephrology, outside the submitted work. PM reports
20 unpaid testimony for AIFA, travel support from his organization, and leadership role
21 in the Italian Society of Nephrology, outside the submitted work. BLN reports
22 personal fees (advisory boards, speaker honoraria) from AstraZeneca and
23 Boehringer and Ingelheim, personal fees (advisory boards) from Alexion, Bayer and
24 Cambridge Healthcare Research, and personal fees (speaker honoraria) from
25 Cornerstone Medical Education, Medscape and The Limbic, outside the submitted
26 work, with all fees paid to The George Institute for Global Health, outside the
27 submitted work. DN reports grants from the UK Health Foundation, NIHR, MRC, and
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 GSK, and leadership role in the UKKA, outside the submitted work. RO reports
4 personal fees from Sanofi, CSL Vifor, and Hansa, and other from Alexion, outside
5 the submitted work. AP reports personal fees from Amgen Hellas E.P.E, Astellas
6 Pharmaceuticals A.E.B.E, Baxter Hellas E.P.E., Genesis Pharma S.A.,
7
8 GlaxoSmithKline A.E.B.E., and Menarini Hellas A.E., outside the submitted work.
9
10 GPB reports personal fees (consultancy honoraria) and other (travel grants) from
11 Fresenius Kabi, outside the submitted work. LP reports personal fees from
12 AstraZeneca, A. Menarini, Boehringer-Ingelheim, Servier, MSD, Novartis, Novo
13 Nordisk, and Vifor Pharma and is President of the Irish Nephrology Society, outside
14 the submitted work. JJR reports personal fees from Novartis, outside the submitted
15 work. MDS reports personal fees from AstraZeneca, personal fees from Boehringer-
16 Ingelheim, personal fees from ViforPharma, personal fees from Baxter, outside the
17 submitted work. MWT reports royalties from Elsevier, grants from Fresenius Medical
18 Care, personal fees from Bayer, personal fees from Boehringer Ingelheim, outside
19 the submitted work; and is Chair of the International Network of CKD Cohorts. ST
20 reports Fellowship grants from the International Society of Nephrology-Salmasi
21 Family and the Kidney Foundation of Thailand, outside the submitted work. RCV
22 reports personal fees from R AstraZeneca, Glaxo Smith Kline, Fresenius Kabi,
23 Novartis, Kibow, Baxter, Nipro, Fresenius Medical Care and Nextkidney, outside the
24 submitted work. TW reports consulting fees from GSK, Astellas, Bayer, Boehringer
25 Ingelheim, AstraZeneca, persone fees from GSK, Bayer, AstraZeneca, outside the
26 submitted work; TW also participates on advisory boards for Bayer, Boehringer
27 Ingelheim, and AstraZeneca, outside the submitted work. DCW reports personal fees
28 (consutancy) from AstraZeneca, and personal fees (honoraria) from Astellas, Bayer,
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Boehringer Ingelheim, Eledon, Galderma, GSK, Jansen, Mundipharma, MSD,
Menorini, ProKidney, Pharmacosmos, Tricida, and Vifor, outside the submitted work.


For Peer Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



2a Chronic Hemodialysis
Rate per million population
 <1.6 1.6 – 4.8 4.9 – 10.7 ≥10.8 Unknown



2b Chronic Peritoneal Dialysis
Rate per million population
 <0.5 0.5 – 1.5 1.6 – 3.0 ≥3.1 Unknown



2c Kidney Transplantation
Rate per million population
 <0.2 0.2 – 0.4 0.5 – 0.7 ≥0.8 Unknown

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Country	Nephrologists	Pediatric nephrologists	Transplant surgeons	Surgeons (HD access)	Surgeons (PD access)	Dietitians	Laboratory technicians	Radiologists (ultrasound)	Vascular access coordinators	Counsellors/ psychologists	Transplant coordinators	Dialysis nurses	Renal nurses	Dialysis technicians	Social workers	Palliative care physicians	Kidney supportive care nurses
Andorra	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Austria	Shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Belgium	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Denmark	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Finland	No shortage	No shortage	No shortage	No shortage	No shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
France	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Germany	Shortage	Shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Greece	Shortage	Shortage	Shortage	No shortage	Shortage	Shortage	Shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
Iceland	Shortage	No shortage	Shortage	No shortage	Shortage	No shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Ireland	No shortage	No shortage	No shortage	Shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Israel	Shortage	No shortage	No shortage	No shortage	No shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Italy	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
Liechtenstein	No shortage	No shortage	No shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Luxembourg	Shortage	Shortage	Shortage	Shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Malta	No shortage	No shortage	Shortage	Shortage	No shortage	Shortage	No shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
Netherlands	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Norway	Shortage	Shortage	No shortage	No shortage	No shortage	Shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
Portugal	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Spain	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage
Sweden	Shortage	No shortage	Shortage	Shortage	Shortage	No shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
Switzerland	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage	Shortage
United Kingdom	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage	No shortage

No shortage

Shortage

1
2
3 **Capacity for the management of kidney failure in the International Society of**
4 **Nephrology Western Europe region: Report from the 2023 ISN Global Kidney**
5 **Health Atlas (ISN-GKHA)**
6
7
8
9

10
11
12
13 **Supplementary Tables and Figure**
14

15
16 **Table S1.** Workforce (specialist physician, doctor, and nurse) prevalences in the ISN
17 Western Europe region.
18

19
20
21 **Table S2.** Healthcare system funding structure for kidney replacement therapy in the
22 ISN Western Europe region [n (100%)].
23

24
25
26 **Table S3.** Availability of in-center hemodialysis, home hemodialysis, and dialysis in
27 the ISN Western Europe region [n (100%)].
28

29
30
31 **Table S4.** Availability of choice-restricted conservative kidney management* in the
32 ISN Western Europe region [n (100%)].
33

34
35
36 **Table S5.** Barriers to optimal kidney care, overall and in the ISN Western Europe
37 region [n (100%)].
38

39
40
41 **Table S6.** National health strategies for non-communicable diseases and CKD-
42 specific policies in the ISN Western Europe region [n (100%)].
43

44
45
46 **Table S7.** Commonest causes of death among people receiving hemodialysis in the
47 ISN Western Europe region [n (100%)].
48

49
50
51 **Table S8.** Commonest causes of death among people receiving peritoneal dialysis in
52 the ISN Western Europe region [n (100%)].
53
54
55
56
57
58
59
60

1
2
3 **Table S9.** Commonest causes of hospitalization amongst people receiving
4 hemodialysis in the ISN Western Europe region [n (100%)].
5
6
7

8 **Table S10.** Commonest causes of hospitalization amongst people receiving
9 peritoneal dialysis in the ISN Western Europe region [n (100%)].
10
11
12

13 **Figure S1.** Country-level scorecard on the availability of KRT, CKM, funding for
14 medications, registry, advocacy group, nephrologists and nephrology trainees in the
15 ISN Western Europe region in 2019 and 2023.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review Only

Table S1. Workforce (specialist physician, doctors, and nurse) prevalences in the ISN Western Europe region**46

	Specialist physician prevalence (per 1000 population)			Medical doctor prevalence (per 1000 population)			Nurse prevalence (per 1000 population)		
	N	Median	[Interquartile range]	N	Median	[Interquartile range]	N	Median	[Interquartile range]
Overall	161	1.95	[0.42 - 3.00]	159	17.74	[3.81 - 32.77]	159	36.20	[14.40 - 66.61]
Western Europe	21	3.87	[3.27 - 4.25]	21	42.25	[34.90 - 50.47]	21	117.80	[88.53 - 167.80]

Data are presented as median (interquartile range).

Abbreviations: ISN, International Society of Nephrology

*; prevalence shown per 1,000 population

Table S2. Healthcare system funding structure for kidney replacement therapy, overall and in the ISN Western Europe region [n (%)].

	Publicly funded by government and free at the point of delivery	Publicly funded by government but with some fees at the point of delivery	A mix of publicly funded (whether or not publicly funded component is free at point of delivery) and private systems	Solely private and out-of-pocket	Solely private through health insurance providers	Multiple systems - programs provided by government, NGOs, and communities	Other	N/A	Total
Overall	74 (45)	32 (19)	38 (23)	7 (4)	2 (1)	9 (5)	3 (2)	1 (1)	166
Western Europe	19 (86)	0 (0)	1 (5)	0 (0)	1 (5)	1 (5)	0 (0)	0 (0)	22

Abbreviations: ISN, International Society of Nephrology; NGOs, non-governmental organizations

Table S3. Availability of in-center hemodialysis, home hemodialysis, and peritoneal dialysis in the ISN Western Europe region [n (%)].

	In-center Hemodialysis			Home Hemodialysis			Peritoneal Dialysis overall			Type of Peritoneal Dialysis available			
	No	Yes	Total	No	Yes	Total	No	Yes	Total	Acute PD only	Acute and chronic PD	Chronic PD only	Total
Overall	3 (2)	162 (98)	165	116 (70)	49 (30)	165	35 (21)	130 (79)	165	4 (3)	86 (66)	40 (31)	130
Western Europe	0 (0)	22 (100)	22	4 (18)	18 (82)	22	0 (0)	22 (100)	22	0 (0)	15 (68)	7 (32)	22

Abbreviations: ISN, International Society of Nephrology; PD, peritoneal dialysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table S4. Availability of choice-restricted conservative kidney management* in the ISN Western Europe region [n (%)].

	Generally available	Generally not available	N/A (not available)	Unknown	Total
Overall	66 (40)	57 (35)	26 (16)	16 (10)	165
Western Europe	9 (41)	0 (0)	4 (18)	9 (41)	22

Abbreviations: ISN, International Society of Nephrology

* This means where there are no resource constraints to prevent or limit access to kidney replacement therapy.

Table S5. Barriers to optimal kidney care, overall and in the ISN Western Europe region [n (%)].

	Geography (distance from care or prolonged travel time)	Physician (availability, access, knowledge, attitude)	Patient (knowledge, attitude)	Nephrologist (availability)	Healthcare system (availability, access, capability)	Lack of political will and enabling policies	Economic factors (limited funding, poor reimbursement mechanisms)	Other	Total
Overall	98 (59)	118 (71)	125 (75)	112 (67)	102 (61)	88 (53)	99 (59)	4 (2)	167
Western Europe	9 (41)	11 (50)	12 (55)	13 (59)	7 (32)	10 (45)	4 (18)	1 (5)	22

Abbreviations: ISN, International Society of Nephrology

Table S6. National health strategies for non-communicable diseases and CKD-specific policies in the ISN Western Europe region [n (%)].

	Non-communicable diseases					National Strategy for improving CKD care					Availability of CKD-specific policies				
	No	Yes, in place	Under development but not yet being implemented	Unknown	Total	No	Yes, a national CKD-specific strategy exists	Yes, but the CKD strategy is incorporated into an NCD strategy that includes other diseases.	Unknown	No	Yes	Unknown	Total		
Overall	29 (18)	91 (56)	19 (12)	23 (14)	162	61 (38)	41 (25)	47 (29)	13 (8)	91 (56)	60 (37)	11 (7)	162		
Western Europe	3 (14)	14 (64)	1 (5)	4 (18)	22	10 (45)	5 (23)	5 (23)	2 (9)	11 (50)	7 (32)	4 (18)	22		

Abbreviations: ISN, International Society of Nephrology; CKD, chronic kidney failure; NCD, non-communicable diseases

Table S7. Commonest causes of death among people receiving hemodialysis in the ISN Western Europe region [n (%)].

	Cardiovascular disease (ischemic heart disease, arrhythmia, cerebrovascular disease)	Infection (access-related infection, infected AVF/AVG, catheter-related bacteremia)	Infection (other sources, pneumonia, gangrene of limbs, etc.)	Malignancy	Dialysis withdrawal (due to social reasons)	Dialysis withdrawal (due to cost of care)	Others	Unknown	Total
Overall	123 (77)	17 (11)	1 (1)	0 (0)	0 (0)	6 (4)	1 (1)	11 (7)	159
Western Europe	21 (95)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	22

Abbreviations: ISN, International Society of Nephrology; CKD, chronic kidney failure; AVF, arteriovenous fistula; AVG, arteriovenous graft

Table S8. Commonest causes of death among people receiving peritoneal dialysis in the ISN Western Europe region [n (%)].

	Cardiovascular disease (ischemic heart disease, arrhythmia, cerebrovascular disease)	Infection (access-related infection, infected AVF/AVG, catheter-related bacteremia)	Infection (other sources, pneumonia, gangrene of limbs, etc.)	Malignancy	Dialysis withdrawal (due to social reasons)	Dialysis withdrawal (due to cost of care)	Others	Unknown	Total
Overall	85 (66)	19 (15)	4 (3)	0 (0)	1 (1)	3 (2)	1 (1)	15 (12)	128
Western Europe	19 (86)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (14)	22

Abbreviations: ISN, International Society of Nephrology; AVF, arteriovenous fistula; AVG, arteriovenous graft;

Table S9. Commonest causes of hospitalization amongst people receiving hemodialysis in the ISN Western Europe region [n (%)].

	Cardiovascular disease (ischemic heart disease, arrhythmia, cerebrovascular disease)	Access malfunction (malfunction AVF/AVG, or blocked central venous catheter)	Access-related infection (infected AVF/AVG, CVC catheter-related bacteremia)	Infection (other sources, pneumonia, gangrene of limbs, etc.)	Others	Unknown	Total
Overall	48 (30)	28 (18)	51 (32)	15 (9)	2 (1)	15 (9)	159
Western Europe	13 (59)	3 (14)	0 (0)	2 (9)	0 (0)	4 (18)	22

Abbreviations: ISN, International Society of Nephrology; AVF, arteriovenous fistula; AVG, arteriovenous graft; CVC, central venous catheter

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Table S10. Commonest causes of hospitalization amongst people receiving peritoneal dialysis in the ISN Western Europe region [n (%)].

	Cardiovascular disease (ischemic heart disease, arrhythmia, cerebrovascular disease)		Access malfunction (PD catheter block, catheter tip migration)		PD-related infection (peritonitis, exit-site or tunnel tract infection)		Infection (other sources, pneumonia, gangrene of limbs, etc.)		Others	Unknown		Total
Overall	27	(21)	17	(13)	65	(51)	5	(4)	0 (0)	14	(11)	128
Western Europe	7	(32)	3	(14)	5	(23)	3	(14)	0 (0)	4	(18)	22

Abbreviations: ISN, International Society of Nephrology; PD, peritoneal dialysis

For Peer Review Only

Figure S1: Country-level scorecard on the availability of KRT, CKM, funding for medications, registry, advocacy group, nephrologists and nephrology trainees in the ISN Western Europe region in 2019 and 2023.

Country		Availability of KRT			Availability of CKM		Funding for Medications			Availability of Distribution of Registry				Advocacy Group			Nephrology Workforce (PMP)	
		HD	PD	KT	Shared decision	Choice restricted (limited)	CKD	Dialysis	KT	CKD	Dialysis	KT	AKI	CKD	AKI	Kidney failure / KRT	Nephrologist	Nephrologist trainees
Andorra	2019																	
	2023																0.00	0.00
Austria	2019																34.12	5.69
	2023																33.66	5.61
Belgium	2019																	
	2023																21.10	4.22
Denmark	2019																25.82	4.48
	2023																25.33	4.05
Finland	2019																14.45	1.81
	2023																19.64	8.93
France	2019																20.04	5.05
	2023																17.57	5.86
Germany	2019																18.64	3.73
	2023																27.01	0.59
Greece	2019																55.75	7.43
	2023																36.07	9.49
Iceland	2019																29.11	
	2023																30.76	0.00
Ireland	2019																9.47	5.92
	2023																11.75	9.48
Israel	2019																29.67	2.37
	2023																24.68	3.93
Italy	2019																48.20	8.03
	2023																	49.10
Liechtenstein	2019																51.88	0.00
	2023																100.73	0.00
Luxembourg	2019																21.46	
	2023																12.30	6.15
Malta	2019																13.36	22.27
	2023																	17.23
Netherlands	2019																17.49	2.33
	2023																15.17	2.30
Norway	2019																27.92	18.61
	2023																27.37	9.00
Portugal	2019																27.52	9.66
	2023																34.17	14.65
Spain	2019																20.27	7.30
	2023																53.01	10.60
Sweden	2019																22.91	8.96
	2023																23.85	6.68
Switzerland	2019																30.15	5.12
	2023																41.13	5.88
United Kingdom	2019																9.78	6.14
	2023																12.13	6.15

Abbreviations: ISN, International Society of Nephrology; KRT, kidney replacement therapy; CKM, conservative kidney management; CKD, chronic kidney disease; AKI, acute kidney injury; KF, kidney failure; KT, kidney transplantation; pmp: per million population

Funding for medications refers to 100% publicly funded by the government (free at the point of delivery).

